Abstract ................................................................................ 590
I. Introduction ............................................................................. 590
II. Cannabinoid CB1 and CB2 receptors and their ligands ................. 591
   A. CB1 and CB2 receptors ...................................................... 591
   B. The endocannabinoid system ............................................. 591
   C. Cannabinoid CB1 and CB2 receptor ligands ......................... 591
      1. Agonists that target CB1 and CB2 receptors with similar potency . 591
      2. CB1- and CB2-selective cannabinoid receptor agonists .......... 593
      3. CB1-selective competitive antagonists .............................. 594
      4. CB2-selective competitive antagonists .............................. 596
      5. Other compounds ...................................................... 596
   D. CB1 receptor homomers and heteromers: nomenclature and pharmacology ........................................ 596
      1. CB1 receptor homomers .................................................. 596
      2. CB1 receptor heteromers: a brief introduction .................. 597
      3. CB1-D2 dopamine receptor heteromers ............................ 597
      4. CB1-opioid receptor heteromers ..................................... 598
      5. CB1-orexin-1 receptor heteromers .................................. 599
      6. Other CB1 receptor heteromers ..................................... 599
III. The extent to which CB1 and CB2 receptor ligands target non-CB1, non-CB2 receptors and ion channels ................................................ 599
   A. The deorphanized G protein-coupled receptor, GPR55 .................. 599
      1. Reported pharmacology of GPR55 .................................... 599
      2. Anandamide ............................................................ 600
      3. 2-Arachidonoyl glycerol .............................................. 600
      4. Lysophosphatidyl inositol ............................................. 601
      5. Δ9-Tetrahydrocannabinol .......................................... 601
      6. Abnormal-cannabidiol .............................................. 601
      7. Cannabidiol ........................................................... 601
      8. O-1602 .................................................................... 601

Address correspondence to: Prof. R. G. Pertwee, School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK. E-mail: rgp@abdn.ac.uk

This article is available online at http://pharmrev.aspetjournals.org.
doi:10.1124/pr.110.003004.
Cannabinoid Receptors and Their Ligands

9. CP55940. ................................................................. 601
10. R(+)-WIN55212. ......................................................... 602
11. Rimonabant. ............................................................... 602
12. AM251 ................................................................. 602
13. Other ligands ............................................................. 602
14. Impact of cell lines and expression levels on GPR55 data . 602
15. Conclusions ............................................................ 602

B. Other deorphanized G protein-coupled receptors . 603
1. GPR40, GPR41, GPR42, and GPR43 ................................ 603
2. GPR84 and GPR120 ..................................................... 604
3. GPR3, GPR6, and GPR12 ............................................. 604
4. GPR18 and GPR92 ....................................................... 604
5. GPR23 ................................................................. 604
6. GPR119 ................................................................. 605
7. Conclusions ............................................................ 605

C. Established G protein-coupled receptors . 605
1. Opioid receptors ........................................................... 605
2. Muscarinic acetylcholine receptors ............................... 606
3. Other established G protein-coupled receptors ................ 606
4. Conclusions ............................................................ 606

D. Ligand-gated ion channels . 606
1. 5-HT₃ receptors .......................................................... 606
2. Nicotinic acetylcholine receptors .................................... 607
3. Glycine receptors ........................................................ 607
4. Other ligand-gated ion channels ...................................... 607
5. Conclusions ............................................................ 608

E. TRPV1 and other transient receptor potential channels . 608
1. Transient receptor potential channels: a brief introduction 608
2. TRPV1 channels ........................................................ 608
3. Other TRPV channels ................................................. 610
4. Other TRP channels: TRPM8 and TRPA1 ....................... 611
5. Conclusions ............................................................ 611

F. Other ion channels .................................................... 611
1. Calcium channels ..................................................... 611
2. Potassium channels ................................................... 612
3. Sodium channels ..................................................... 613
4. Conclusions ............................................................ 614

G. Peroxisome proliferator-activated receptors . 614
1. Direct evidence for peroxisome proliferator-activated receptor activation or occupancy by cannabinoids and related molecules . 614
2. Indirect evidence for cannabinoid activation of peroxisome proliferator-activated receptors ........................................ 615
3. Reporter gene assays and metabolism of endocannabinoids ................................................... 615
4. Antagonism ............................................................. 615
5. Genetic disruption ....................................................... 615
6. Amplification of endocannabinoid levels and peroxisome proliferator-activated receptors .......................................... 615
7. Regulation by peroxisome proliferator-activated receptors and peroxisome proliferator-activated receptor ligands of the endocannabinoid system ........................................ 616
8. Conclusions ............................................................ 616

H. Some putative receptors . 617
1. Imidazoline-like receptors ........................................... 617
2. The putative abnormal-cannabidiol receptor ..................... 617
3. A putative receptor for anandamide and R(+)-WIN55212 . 617
4. The putative CB₂sc receptor for R(+)-WIN55212 .............. 618

IV. Phylogenetic relationships ........................................... 619
A. CB₁, CB₂, and other rhodopsin α group-type G protein-coupled receptors ........................................ 619
B. GPR55 and other rhodopsin δ group-type G protein-coupled receptors ........................................ 620
Abstract—There are at least two types of cannabinoid receptors (CB1 and CB2). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid Δ^2-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endocannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB1, non-CB2 established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB1, and/or CB2 receptors are likely to display significanty different pharmacological profiles. The review also lists some criteria that any novel “CB3” cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB1, non-CB2 pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB1, receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB3 receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB1/CB2 receptors and other GPCRs, 3) evidence for the existence of as-yet-uncharacterized non-CB1, non-CB2 cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

I. Introduction

The main purpose of this review is to consider current knowledge about the extent to which established cannabinoi CB1 and CB2 receptor ligands target non-CB1, non-CB2 receptors or ion channels (section III). These considerations are preceded by a brief overview of the pharmacology of cannabinoid CB1 and CB2 receptors and their ligands and by a discussion of the evidence that CB1 receptors form heteromeric complexes with [b,d]pyran, LOX, lipoxigenase; LPA, lysophosphatidic acid; LPI, lysophosphatidyl inositol; LY325345, 4-[6-methoxy-2-(4-methoxyphenyl)-3-benzofuran]yl[carboxy]benzonitrile; MAPK, mitogen-activated protein kinase; MK886, 1-[4-(chlorophenyl)methyl]-3-[1,1-dimethylthiol]α,α-dimethyl-5-[1-(methyl)phenyl]-3-(1-methanesulfo-nyl)-D-aspartate; noladin ether, 2-arachidonoyl glycerol; abn-CBD, abnormal-cannabidiol; ACEA, arachidonyl-2-chloroethylamide; AM1241, R-(2-s-docosyl-5-benzoxazinyl)-1-methylbenzamide; AM2205, N-(piperidin-1-yl)-5-[4-(iodophenyl)]-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; AM261, 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-[4-morpholinyl]-1H-pyrazole-3-carboxamide; AM404, N-(4-hydroxyphenyl)-5Z,5Z,11Z,14Z-eicosatetraenoic acid; AM630, [6-iodo-2-methyl-1-[2-(4-morpholino)ethyl]-1H-indol-3-yl]-4-methoxyphenyl)methanol (6-indopravadoline); CHO, Chinese hamster ovary; COX, cyclooxygenase; CP55940, (-cis-3-[2-hydroxy-4,1,1,6,6,6-decamethylheptyl]phenyl(trans)-4-[3-hydroxypropyl]cyclohexanol; CT-3, ajulemic acid; DAMGO, [b-Ala^2,N-Me-Phe^4,Gly-OH]-enkephalin; DRG, dorsal root ganglion; ERK, extracellular-signal regulated kinase; FAAH, fatty acid amide hydrolase; FRET, fluorescence resonance energy transfer; FTY720, 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol; GLF-1, glucagon-like peptide-1; GPCR, G protein-coupled receptor; GTPγS, guanosine 5′-O-(3-thiotriphosphate; GW6471, [2S]-2-[[1Z]-1-methyl-3-oxo-3-[4-( trifluoromethyl)phenyl]1-propenyl]amino]-3-[4-(5-methyl-2-phenyl-4-oxoazolyl)ethyl]phenyl-carboxylic acid ethyl ester; GW7647, 2-[[2-[4-(carboxy)ethyl]amino]carboxyl]-4[4-cyclohexylbutylamino]ethyl]-phenyl[d-thio]-2-methylenepropionic acid; GW9662, 2-chloro-5-nitro-N-phenylbenzamide; HEK, human embryonic kidney; HU-210, 6(R)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methyl; HU243, [6(R)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methyl; HU-308, 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-yl]methanol; HU-331, 3S,4S,5S-ar-benzoquinone; 3-hydroxy-2-pmentha-(1,8-dien-3-yl)-5-pentyl; JTE-907, N-(1,3-benzodioxol-5-ylmethyl]-1,2-dihydro-7-methoxy-2-oxo-8-(pentyl-1)-2,3-dihydroquinolinecarboxamide; JW1005, (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; JW-133, (6R,10aR)-3-[1,1-dimethylbutyl-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo
cannabinoid receptors and their ligands

II. Cannabinoid CB1 and CB2 Receptors and their Ligands

A. CB1 and CB2 Receptors

The discovery in 1990 that an orphan G protein-coupled receptor (SKR6) derived from a rat cerebral cortex cDNA library mediates pharmacological effects of (−)-Δ9-tetrahydrocannabinol (Δ9-THC1), the main psychoactive constituent of cannabis, established the identity of the first cannabinoid receptor, which we now refer to as CB1 (Matsuda et al., 1990). Three years later, in 1993, a G protein-coupled receptor (CX5) expressed in the human promyelocytic leukemia cell line HL60 was identified as a second cannabinoid receptor and named CB2 (Munro et al., 1993). CB1 and CB2 receptors are members of the superfamily of G protein-coupled receptors (GPCRs). As discussed in greater detail elsewhere (Howlett et al., 2002; Howlett, 2005), both these receptors inhibit adenylyl cyclase and activate mitogen-activated protein kinase by signaling through Gi/o proteins, which for the CB1 receptor can also mediate activation of A-type and inwardly rectifying potassium currents and inhibition of N- and P/Q-type calcium currents. In addition, CB1 receptors can signal through Gs proteins (Glass and Felder, 1997; Maneuf and Brotchie, 1997; Calandra et al., 1999; Jarrahan et al., 2004). The ability of CB1 and CB2 receptors to signal through Gi/o proteins and, further downstream, through adenylyl cyclase is frequently exploited in two widely used in vitro bioassays: the [35S]GTPγS binding assay and the cAMP assay (Howlett et al., 2002; Pertwee, 2005a). As well as orthosteric site(s), the CB1 receptor possesses one or more allosteric sites that can be targeted by ligands in a manner that enhances or inhibits the activation of this receptor by direct agonists (Price et al., 2005a; Adam et al., 2007; Horswill et al., 2007; Navarro et al., 2009).

CB1 receptors are found mainly at the terminals of central and peripheral neurons, where they usually mediate inhibition of ongoing release of a number of different excitatory and inhibitory neurotransmitters (for review, see Howlett et al., 2002; Pertwee and Ross, 2002; Szabo and Schlicker, 2005). The distribution of these receptors within the central nervous system is such that their activation can affect processes such as cognition and memory, alter the control of motor function, and induce signs of analgesia. As to CB2 receptors, these are located predominantly in immune cells and, when activated, can modulate immune cell migration and cytokine release both outside and within the brain (for review, see Howlett et al., 2002; Cabral and Staab, 2005; Pertwee, 2005a). There is also evidence that 1) some CB1 receptors are expressed by non-neuronal cells, including immune cells (Howlett et al., 2002), and 2) that CB2 receptors are expressed by some neurons, both within the brain and elsewhere (Skaper et al., 1996; Ross et al., 2001a; Van Sickel et al., 2005; Wooterspoon et al., 2005; Beltramo et al., 2006; Gong et al., 2006; Baek et al., 2008). The role of neuronal CB2 receptors remains to be established.

Finally, several polymorphisms in the genes of CB1 (CNR1) and CB2 (CNR2) receptors and in their proteins have been identified. Some of these have been linked to certain disorders that for CNR1 include 1) schizophrenia and 2) depression in Parkinson’s disease and for CNR2 include postmenopausal osteoporosis (for review, see Norrod and Puffenbarger, 2007; Henquet et al., 2008; Bab et al., 2009).

B. The Endocannabinoid System

The cloning of the CB1 receptor was followed by the discovery that mammalian tissues can both synthesize cannabinoid receptor agonists and release them onto cannabinoid receptors. The first of these “endocannabinoids” to be identified were N-arachidonoyl ethanolamine (anandamide) and 2-arachidonoyl glycerol (2-AG) (Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995), both of which are synthesized on demand in response to elevations of intracellular calcium (for review, see Di Marzo et al., 2005). Other compounds may also serve as endocannabinoids. These include N-dihomo-γ-linolenoyl ethanololamine, N-docosatetraenoyl ethanolamine, O-arachidonoyl ethanolamine (virodhamine), oleamide, N-arachidonoyl dopamine and N-oleoyl dopamine (for review, see Pertwee, 2005b). Endocannabinoids and their receptors constitute the “endocannabinoid system.”

C. Cannabinoid CB1 and CB2 Receptor Ligands

1. Agonists that Target CB1 and CB2 Receptors with Similar Potency. Several cannabinoid receptor agonists possess similar affinities for CB1 and CB2 receptors (Table 1). When classified according to their chemical structures (Fig. 1), these agonists fall essentially into four main groups: classical, nonclassical, aminoal-
kylindole, and eicosanoid (for review, see Pertwee, 1999, 2005a, 2008a,b; Howlett et al., 2002).

The classical group consists of dibenzopyran derivatives. It includes Δ⁹-THC, the main psychoactive constituent of cannabis, and (6αR)-trans-3-(1,1-dimethylheptyl)-6α, 7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU-210), a synthetic analog of (−)-Δ⁶-tetrahydrocannabinol. HU-210 displays high affinity for CB₁ and CB₂ receptors and also high potency and relative intrinsic activity as a cannabinoid receptor agonist. These properties are all thought to result mainly from the presence of its dimethylheptyl side chain. Δ⁹-THC possesses significantly lower CB₁ and CB₂ affinity than HU-210 and lower relative intrinsic activity at these receptors, an indication that Δ⁹-THC is a cannabinoid receptor partial agonist. Moreover, it displays even less relative intrinsic activity at CB₂ than at CB₁ receptors.

The nonclassical group contains bicyclic and tricyclic analogs of Δ⁹-THC that lack a pyran ring. A well known member of this group is (−)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol (CP55940). This has been found to have slightly lower CB₁ and CB₂ affinities than HU-210 in some investigations but does seem to possess HU-210-like CB₁ and CB₂ receptor relative intrinsic activity.

Members of the aminoalkylindole group of cannabinoid CB₁/CB₂ receptor agonists have structures that differ markedly from those of both classical and nonclassical cannabinoids. The best known member of this group is R-(+)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate [R-(+)-WIN55212]. This displays CP55940-
and HU-210-like relative intrinsic activity at both CB₁ and CB₂ receptors. However, unlike HU-210 and CP55940, it has been found in some investigations to possess slightly higher CB₂ than CB₁ affinity.

- Members of the eicosanoid group of cannabinoid CB₁/CB₂ receptor agonists have structures quite unlike those of classical, nonclassical, or aminoalkylindole cannabinoids. Two prominent members of this group are the endocannabinoids anandamide and 2-AG. Like /\(^9\)THC, anandamide behaves as a CB₁ and CB₂ receptor partial agonist and displays lower relative intrinsic activity for CB₂ than for CB₁. Its affinity for the CB₁ receptor is also similar to that of /\(^9\)THC. This eicosanoid does, however, have slightly lower receptor affinity for CB₂ than for CB₁ and consequently displays less affinity for the CB₂ receptor than /\(^9\)THC. 2-AG also has slightly less receptor affinity for CB₂ than for CB₁. It seems to have lower CB₁ receptor potency than CP55940 but higher CB₁ and CB₂ receptor potency than anandamide and higher CB₁ receptor relative intrinsic activity than anandamide or CP55940.

2. CB₁ and CB₂-Selective Cannabinoid Receptor Agonists. Compounds that are significantly more potent at activating CB₁ than CB₂ receptors include three synthetic analogs of anandamide (Table 1 and Fig. 2): /\(^{-}\)WIN55212, anandamide, and 2-AG.
potency and relative intrinsic activity as a CB₁ receptor agonist. ACEA and arachidonylcyclopropylamide are both substrates for the anandamide-metabolizing enzyme fatty acid amide hydrolase, whereas this enzyme does not readily hydrolyze $R$-(+)-methanandamide. Noladin ether (2-arachidonyl glyceryl ether) (Hanus et al., 2001) is also a CB₁-selective agonist. It has been reported to possess CP55940-like CB₁ receptor relative intrinsic activity but less potency as a CB₁ receptor agonist than either CP55940 or 2-AG (Suhara et al., 2000, 2001; Savinainen et al., 2001, 2003). As to CB₂-selective agonists (Table 1 and Fig. 2), those most frequently used as pharmacological tools are (6a$^{R}$,10a$^{R}$)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6$^H$-dibenzo[b,d]pyran (JWH-133; a classical cannabinoid), {4-[4-(1,1-dimethylheptyl)-2,6-dimethoxy-phenyl]-1-(2,4-dichlorophenyl)-4-methyl-1$^H$-pyrazole-3-carboxamide (AM251), 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1$^H$-pyrazole-3-carboxamide (AM281), 4-[6-methoxy-2-(4-methoxyphenyl)-3-benzofuranyl|carbonyl] benzonitrile (LY320135), and taranabant (Fig. 3) can all block agonist-induced activation of cannabinoid CB₁ receptors in a competitive manner and bind with significantly greater affinity to cannabinoid CB₁ than cannabinoid CB₂ receptors (Table 1). Although these compounds lack any ability to activate CB₁ receptors when administered alone, there is evidence that in some CB₁ receptor-containing tissues, they can induce responses opposite in direction from those elicited by a CB₁ receptor agonist (Pertwee, 2005c; Fong et al., 2007). In some instances, at least, this may reflect an ability of these compounds to decrease the spontaneous coupling of CB₁ receptors to their effector mechanisms that it is thought can occur in the absence of

3. **CB₁-Selective Competitive Antagonists.** As discussed in greater detail elsewhere (Pertwee, 1999, 2005a, 2008b; Howlett et al., 2002; Fong et al., 2007), the diarylpyrazole rimonabant (SR141716A), $N$-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1$^H$-pyrazole-3-carboxamide (AM251), 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1$^H$-pyrazole-3-carboxamide (AM281), 4-[6-methoxy-2-(4-methoxyphenyl)-3-benzofuranyl|carbonyl] benzonitrile (LY320135), and taranabant (Fig. 3) can all block agonist-induced activation of cannabinoid CB₁ receptors in a competitive manner and bind with significantly greater affinity to cannabinoid CB₁ than cannabinoid CB₂ receptors (Table 1). Although these compounds lack any ability to activate CB₁ receptors when administered alone, there is evidence that in some CB₁ receptor-containing tissues, they can induce responses opposite in direction from those elicited by a CB₁ receptor agonist (Pertwee, 2005c; Fong et al., 2007). In some instances, at least, this may reflect an ability of these compounds to decrease the spontaneous coupling of CB₁ receptors to their effector mechanisms that it is thought can occur in the absence of
exogenously added or endogenously released CB₁ agonists. There is also evidence that at least one of these compounds, rimonabant, can produce inverse cannabimimetic effects in a CB₁ receptor-independent manner (Breivogel et al., 2001; Savinainen et al., 2003; Cinar and Szücs, 2009).

Some CB₁ receptor competitive antagonists have been developed that lack any detectable ability to induce signs of inverse agonism at the CB₁ receptor when administered alone. One example of such a “neutral” antagonist (Table 1) is N-piperidinyl-[8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide] (NESS O327) (Fig. 4), which is a structural analog of rimonabant and displays markedly higher affinity for CB₁ than for CB₂ receptors. This compound behaves as CB₁ receptor antagonist both in vitro and in vivo and yet, by itself, does not affect [³⁵S]GTPγS binding to rat cerebellar membranes (Ruiu et al., 2003). Several other compounds have been reported to behave as neutral cannabinoid CB₁ receptor antagonists (Pertwee, 2005a). These include (6αR,10αR)-3-(1-methanesulfonylamino-4-
hexyn-6-y1)-6a,7,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (O-2050) (Fig. 4), a sulfonamide analog of Δ²-tetrahydrocannabinol with an acetylenic side chain. It is noteworthy that the classification of this compound as a neutral antagonist is based on a very limited set of data, prompting a need for further research into its CB₁ receptor pharmacology.

4. CB₂-Selective Competitive Antagonists. [6-Iodo-2-methyl-1-[2-[4-morpholinyl]ethyl]-1H-indol-3-yl] (4-methoxyphenyl) methanone (6-iodopradavoline) (AM630) and the diarylpyrazole N-[1(S)-endo-1,3,3 trimethyl bicyclo [2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528) (Fig. 3) are both more potent at blocking CB₂ than CB₁ receptor activation. They display much higher affinity for CB₂ than for CB₁ receptors (Table 1) and block agonist-induced CB₂ receptor activation in a competitive manner (for review, see Pertwee, 1999, 2005a, 2008b; Howlett et al., 2002). Both these compounds are thought to be CB₂ receptor inverse agonists rather than neutral antagonists, because when administered by themselves, they can produce inverse cannabimimetic effects in CB₂ receptor-expressing tissues (Rinaldi-Carmona et al., 1998; Ross et al., 1999). Other notable examples of CB₂-selective cannabinoid receptor antagonists/inverse agonists include N-(1,3-benzodioxol-5-ylmethyl)-1,2 dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide (JTE-907) (Iwamura et al., 2001) (Table 1) and the triaryl bis-sulfones N-[1(S)-4-[4-methoxy-2-[(4-methoxy phenyl)sulfonyl]phenyl]sulfonyl]phenyl]ethyl)methanesulfonamide (Sch.225336), N-[1(S)-4-[4-chloro-2-[(2-fluorophenyl)sulfonyl]phenyl]phenyl]ethyl] methanesulfonamide (Sch.356036), and N-[1(S)-4-[4 chloro-2-[(2-fluorophenyl)sulfonyl]phenyl]phenyl]phenyl]ethyl]-1,1,1-trifluoromethanesulfonamide (Sch.414319) (for review, see Lunn et al., 2008). A neutral antagonist that selectively targets the CB₂ receptor has not yet been developed.

5. Other Compounds. Several other compounds that target cannabinoid CB₁ and/or CB₂ receptors with significant potency are mentioned in one or more subsequent sections of this review. The structures of these compounds and their affinities for CB₁ and/or CB₂ receptors are shown in Fig. 5 and Table 1, respectively. Two of these compounds, 11-hydroxy-Δ⁸-tetrahydrocannabinol and ajulemic acid (CT-3), are classical cannabinoids. 11-Hydroxy-Δ⁸-tetrahydrocannabinol possesses slightly greater potency than Δ⁹-THC as an inhibitor of adenylyl cyclase in murine neuroblastoma cells (Howlett, 1987). Compared with CP55940, ajulemic acid displays similar relative intrinsic activity but lower potency at both CB₁ and CB₂ receptors (Dyson et al., 2005). Three of the other compounds are plant cannabinoids (phytocannabinoids). They include cannabiol, which seems to be a CB₁ receptor partial agonist (for review, see Pertwee, 1999). There have also been reports that cannabiol behaves as a reasonably potent CB₂ receptor agonist in the cAMP assay but as a CB₂ receptor inverse agonist in the [³⁵S]GTPγS assay (for review, see Pertwee, 1999). The other two phytocannabinoids, cannabidiol and cannabigerol, seem to be CB₁ receptor antagonists/inverse agonists (Thomas et al., 2007; Cascio et al., 2010). In contrast, two structural analogs of cannabidiol, normal-cannabidiol and 5-methyl-4-[(1R,6R)-3-methyl-6 (prop-1-en-2-yl)cyclohex-2-enyl]benzene-1,3-diol (O 1602) (Fig. 5) that are mentioned in sections III.A.6, III.A.7, III.A.8, and/or III.H.2, lack significant affinity for the CB₁ receptor (for review, see Pertwee, 2004, 2005a). Cannabidiol has also been reported to display significant potency in vitro as a CB₂ receptor antagonist/inverse agonist (for review, see Thomas et al., 2007).

Two other compounds listed in Table 1 are the endogenous eicosanoids vio rhodamine and N-arachidonoyl dopamine. In one investigation, vio rhodamine was found to activate CB₂ receptors and to exhibit either partial agonist or antagonist activity at CB₁ receptors (Porter et al., 2002). However, in another investigation, it was found to behave as a CB₁ receptor antagonist/inverse agonist (Steffens et al., 2005). As for N-arachidonoyl dopamine, there is evidence that this is a moderately potent CB₁ receptor agonist (for review, see Bradshaw and Walker, 2005). It is also noteworthy that N-oleyl dopamine (sections III.B and III.E) possesses some affinity for the CB₁ receptor (Bradshaw and Walker, 2005). However, four other pharmacologically active endogenous acylethanolamides mentioned in sections III and/or IV do not seem to display significant affinity for CB₁ and/or CB₂ receptors. These are linoleoyl ethanolamide, oleoyl ethanolamide, palmitoyl ethanolamide, and stearyl ethanolamide (Lin et al., 1998; Mac carrone et al., 2002; Pertwee, 2004; Bradshaw and Walker, 2005). There have been reports too by Yin et al. (2009) and Kapur et al. (2009) that neither CB₁ nor CB₂ receptors are activated by the putative endogenous GPR55 agonist lysophosphatidyl inositol (section III.A).
Mackie, 2005). Insufficient evidence currently exists to allow any firm conclusions to be drawn about whether monomeric and homomeric forms exhibit differential signal transduction or intracellular trafficking patterns, or how interconversion is physiologically regulated.

2. CB₁ Receptor Heteromers: A Brief Introduction. CB₁ receptors associate with other GPCRs to form heteromeric complexes (within 50–100 Å) as detected by fluorescence (FRET) or bioluminescence resonance energy transfer (El lis et al., 2006; Rios et al., 2006; Carriba et al., 2008; Marcellino et al., 2008). Guidelines for the nomenclature of associated GPCR proteins define receptor heteromers as “macromolecular complexes composed of functional receptor units with biochemical properties that are different from those of its individual components” (Ferre ´ et al., 2009a). A multimeric complex would be expected to influence agonist responses in an allosteric manner (Milligan and Smith, 2007). The guidelines defined allosteric interaction in the receptor heteromer as the “intermolecular interaction by which binding of a ligand to one of the receptor units in the receptor heteromer changes the binding properties of another receptor unit” (Ferre ´ et al., 2009a). Several “CB-X receptor heteromers” conform to the proposed conventions for structurally associated pairs in which the functional interactions influence ligand selectivity or relative intrinsic activity.

3. CB₁-D₂ Dopamine Receptor Heteromers. CB₁-D₂ dopamine receptor heteromers were observed in FRET studies of D₂-green fluorescent protein and CB₁-yellow fluorescent protein fusion proteins expressed in HEK293 cells, with similar D₂-CB₁ receptor dimerization observed in the absence or presence of the CB₁ agonist HU-210, D₂

![Diagram of cannabinoid receptor ligands]

Fig. 5. The structures of (-)-11-hydroxy-Δ⁸-tetrahydrocannabinol, ajulemic acid, cannabinol, cannabidiol, abnormal-cannabidiol, O-1602, cannabigerol, virodhamine, and N-arachidonoyl dopamine.
agonist quinpirole, or both together (Marcellino et al., 2008). However, communoprecipitable complexes solubilized from a HEK293 cell heterologous expression system were promoted by the presence of agonists for both D2 and CB1 receptors (Kearn et al., 2005). Signal transduction in response to agonist stimulation of either CB1 or D2 receptors expressed alone in HEK293 cells is characterized by the Gi/o-dependent inhibition of forskolin-activated adenylyl cyclase (Jarrahian et al., 2004; Kearn et al., 2005). However, coexpression of both CB1 and D2 receptors caused the effect of CP55940 on cAMP production to switch from inhibition to stimulation (Jarrahian et al., 2004). Combining agonists for both CB1 and D2 receptors also promoted a stimulation of cAMP accumulation when both receptors were expressed (Kearn et al., 2005). Synergistic activation of MAPK was also observed in response to simultaneous stimulation by both cannabinoid and dopaminergic agonists (Kearn et al., 2005). Neither the stimulation of cAMP production nor the activation of MAPK was pertussis toxin-sensitive, suggesting that Gi0 proteins were not required for the heterodimer responses to agonists in the HEK293 cell model (Kearn et al., 2005). However, Goi1 overexpression inhibited cAMP production, suggesting that CB1-D2 receptor heteromers could interact with Gi only if the environment is not rich in Gi (Jarrahian et al., 2004). Desensitization of the D2-dopamine receptors by pretreatment with quinpirole reversed the ability of CP55940 to stimulate cAMP production (Jarrahian et al., 2004). Evidence can be found to support the hypothesis that CB1-D2 receptor heteromers function in vivo to convert the G protein preference from Gt to Gi. CP55940 decreased the high and low Kd affinities for dopamine (a function of the receptor-G protein interaction) in equilibrium binding assays of D2 receptors in rat striatal membranes (Marcellino et al., 2008). Cannabinoid and D2 agonists converged to inhibit forskolin-activated adenylyl cyclase as a subadditive response in rodent and monkey striatal membranes (Meschler and Howlett, 2001). In cultured striatal cells, costimulation by dopaminergic and cannabinoid agonists converted the response from a Gi-mediated inhibition to a Gt-mediated stimulation of cAMP production (Glass and Felder, 1997). R(-)-WIN55212-stimulation was reported to increase cAMP accumulation in globus pallidus slices (Manef and Brothie, 1997). Observations of cannabinoid-stimulated protein kinase A activation suggests that cAMP production is a viable signaling mechanism in basal ganglia (Andersson et al., 2005; Borgkvist et al., 2008). However, caution should be observed in interpreting in vivo data, in that D1 dopamine (Bidaut Russell and Howlett, 1991; Meschler and Howlett, 2001) and A2a adenosine receptors (Carnia et al., 2007, 2008; Marcellino et al., 2008) might contribute as components of a heteromeric complex. Immunocytochemical studies suggest that coexpression of CB1 and D2 receptors occurs on the output neurons of the olfactory tubercle, striatum, hippocampus, or neocortex (Hermann et al., 2002). Colocalization of CB1 and D2 receptors has been clearly identified in immunoelectron micrographs at the plasma membrane and endomembrane in dendritic spines in the nucleus accumbens (Pickel et al., 2006). However, it should be noted that these receptors can also be found individually distant from each other in the same soma or dendrite, or trans-synaptically (Pickel et al., 2006).

4. CB1-Opioid Receptor Heteromers. CB1-opioid receptor heteromer formation was detected by an increased bioluminescence resonance energy transfer signal in HEK293 cells coexpressing recombinant yellow fluorescent protein-tagged CB1 and luciferase fused with μ-, δ-, or κ-opioid receptors (Rios et al., 2006). However, functional interaction between CB1 and opioid receptors has thus far been reported only for the CB1-μ-opioid receptor pair. CB1-μ-opioid receptor association may be a factor in intracellular compartmentalization (Canals and Milligan, 2008). Morphine-stimulated [35S]GTPγS binding in HEK293 cells coexpressing CB1 receptors and μ-opioid receptors was attenuated by R(-)-WIN55212 when calculated as a percentage of basal binding (Rios et al., 2006). However, expression of CB1 receptors with μ-opioid receptors in HEK293 cells increased basal [35S]GTPγS binding such that subsequent stimulation by the μ-opioid receptor agonist [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) seemed to be reduced with respect to basal levels (Canals and Milligan, 2008). Basal [35S]GTPγS binding in the CB1-expressing cells was reversed by the CB1 antagonist LY330135, suggesting that the exogenously expressed CB1 receptors were able to constitutively activate a pool of G proteins (Canals and Milligan, 2008). CB1 receptor expression could constitutively reduce morphine- or DAMGO-stimulated MAPK activation in the absence of cannabinoid agonists, and this effect could be blocked by rimonabant but not by the putative neutral CB1 receptor antagonist, O-2050 (Canals and Milligan, 2008). Cannabinoid or opioid agonist actions in the coexpressed receptor model mutually reduced the ability of agonists at the heteroreceptor to activate MAPK (Rios et al., 2006). In Neuro-2A cells expressing CB1 receptors and μ-opioid receptors, simultaneous application of agonists for both receptors suppressed Src and signal transducer and activator of transcription 3 phosphorylation and neurite outgrowth in a reciprocal manner. These findings, in total, would be consistent with mutual heterotropic allosterism. Nevertheless, caution must be exercised when interpreting signal transduction outcomes in heterologous expression systems, because the influence of membrane localization, protein stoichiometry, and accessory proteins may be missing (Shapira et al., 1998, 2000). Finally, CB1-μ-opioid receptor heteromers may function in cellular models that endogenously express both receptors. In SK-N-SH neuroblastoma and rat striatal membranes, stimulation of [3H]GTPγS binding by the CB1 agonist R(-)-WIN55212 was reduced by the μ-opioid agonist DAMGO, as was DAMGO-induced stimulation of [3H]GTPγS binding by R(+)-WIN55212 (Rios et al., 2006). Furthermore, immunoelectron microscopy studies demonstrated that CB1 receptors and μ-opioid recep-
tors colocalize in dendritic spines of the medium spiny neurons of the striatum as well as in interneurons of the dorsal horn of the spinal cord (Rodríguez et al., 2001; Salio et al., 2001; Pickel et al., 2004). However, in interpreting in vivo data, researchers should be cognizant that these receptors are also distributed individually and trans-synaptically (Pickel et al., 2004).

5. CB1/Orexin-1 Receptor Heteromers. Evidence for CB1–orexin-1 (OX1) receptor heteromers comes from observations that when expressed in CHO cells, these receptors appear as clusters at the plasma membrane in immunoelectron micrographs (Hilairet et al., 2003). FRET studies demonstrated close proximity of the CB1- and OX1-fluorescent fusion proteins expressed in HEK293 cells (Ellis et al., 2006). Although agonists activated MAPK in both of these receptors when expressed individually in CHO cells, coexpression resulted in a 100-fold increase in MAPK sensitivity to orexin A, a response that was reversed by the CB1 antagonist rimonabant or by pertussis toxin treatment (Hilairet et al., 2003). On the other hand, coexpression had no appreciable effect on the potency of CP55940 to stimulate MAPK or to inhibit adenylyl cyclase (Hilairet et al., 2003). CB1 and OX1 receptors were coexpressed predominantly in intracellular vesicles (Ellis et al., 2006). Treatment with antagonists for either receptor (CB1, rimonabant; OX1, SB674042) promoted trafficking of both receptors to the cell surface (Ellis et al., 2006), suggesting that CB1–OX1 receptor heteromerization influences cellular translocation of these receptors.

6. Other CB1 Receptor Heteromers. Evidence that CB1 and GPCRs, in addition to D2, opioid, or OX1 receptors, may form receptor heteromers is based upon pharmacological cross-talk data, and until other kinds of data become available to support the existence of receptor heteromers, judgement on these pairs must be withheld. The GABA_B antagonist phaclofen noncompetitively antagonized R-(-)-WIN55212-stimulated [35S]GTPγS binding in hippocampal membranes, and a CB1 antagonist competitively antagonized the response to 3-aminopropyl(methyl)phosphonic acid (SKP97541) (Cinar et al., 2008). Agonist-stimulation of CB1 and GABA_B receptors, both endogenously expressed in cerebellar granule cells, resulted in a subadditive inhibition of adenylyl cyclase (Childers et al., 1993; Pacheco et al., 1993). The response to agonists for α2- adrenoceptor- or somatostatin receptor-mediated inhibition of N-type Ca2+ channels was reduced by expression of exogenous CB1 receptors in superior cervical ganglia neurons (Pan et al., 1998; Vásquez and Lewis, 1999). This effect of CB1 receptor expression could be reversed by overexpression of exogenous Goαlq, Gβ1, and Gγ3 (Vásquez and Lewis, 1999), suggesting that these receptors may exist in a complex with shared Goα proteins required for Ca2+ channel regulation. The multiplicity of possible receptor “modules” that comprise functional units of signal transduction activity with other receptors, ion channels, and signal transducing effectors points to the complexity involved in interpreting data from in vivo studies (Fuxe et al., 2008; Ferré et al., 2009b). Future investigations must determine the proximity of these receptors to each other, and provide definitive evidence for heterotropic allosteric interactions before these protein pairs can be advanced as receptor heteromer candidates.

III. The Extent to Which CB1 and CB2 Receptor Ligands Target Non-CB1, Non-CB2 Receptors and Ion Channels

A. The Deorphanized G Protein-Coupled Receptor, GPR55

Human GPR55 (hGPR55) was originally isolated in 1999 as an orphan GPCR with high levels of expression in human striatum (Sawzdargo et al., 1999) (GenBank accession no. NM_005683.3) and its gene mapped to human chromosome 2q37. GPR55 belongs to group δ of the rhodopsin-like (class A) receptors (Fredriksson et al., 2003b) and shows low sequence identity to both CB1 (13.5%) and CB2 (14.4%) receptors, which belong to group α of the class A GPCRs. A genetics study (McPartland et al., 2006) has investigated the origins of the cannabinoid system and has concluded with respect to GPR55 that there is no significant sequence similarity between itself and CB1 or CB2. In particular, there is little sequence similarity in the areas responsible for ligand binding. Initial characterization of human GPR55 identified it as a potential member of either the purinergic or chemokine receptor family based on amino acid homology. However, it is most closely related (30% similarity) to GPR23/LPA4 (GenBank accession no. NM_005296.2), and GPR92/LPA5 (GenBank accession no. NM_024040.5) which have been shown to be lysophosphatidic acid (LPA) receptors (Noguchi et al., 2003; Kotarsky et al., 2006; Lee et al., 2006) (sections III.B.4 and III.B.5). It also shares 29% identity with P2Y5/LPA6 (GenBank accession no. NM_005767.4), also shown to be a LPA receptor (Pasternack et al., 2008), 27% identity with GPR35 (GenBank accession no. NM_005301.2), and 23% identity with the CCR4 chemokine receptor (GenBank accession no. NM_005508.4) (Sawzdargo et al., 1999).

1. Reported Pharmacology of GPR55. The current pharmacology of ligands at GPR55 is complicated and inconsistent. There are 11 reports containing data relating to ligand activity at GPR55. These reports use eight different cell backgrounds and six different assay endpoints that are all dependent on functional assays. So far, no binding data have been published. There are few examples of more than one laboratory repeating similar studies using equivalent cell background and assay technology. A range of assay strategies have been used to investigate the pharmacology of GPR55 and the mechanism of downstream signaling by this receptor remains uncertain. Using an approach that uses 12-amino acid peptides equivalent to the C-terminal sequences of the G proteins Goα12, Goα13, Goαs, and Goα13, as well as antibodies raised against those same peptides, it was demonstrated that the G protein preferentially coupling to GPR55 in [35S]GTPγS binding assays was Goα13.
GPR55 has also been shown by other methods to use G_{i}, G_{12,}, or G_{13} for signal transduction, which results in downstream activation of RhoA and PLC (Lauckner et al., 2008; Henstridge et al., 2009; Kapur et al., 2009). This signaling mode is associated with temporal changes in cytoplasmic calcium, membrane-bound diacylglycerol, and plasma membrane topology. Involvement of the actin cytoskeleton has also been reported by Lauckner et al. (2008). The reported activities of different ligands at GPR55 in various assays are summarized below and in Table 2.

2. Anandamide. The endocannabinoid ligand anandamide (section II.C.1) possesses significant affinity for both CB1 and CB2 receptors with slightly greater affinity for CB1 than for CB2 (Table 1). Using a [^{35}S]GTP_{S} binding assay, Ryberg et al. (2007) found that this ligand has an EC_{50} of 18 nM at GPR55 expressed in HEK293 cells and that it seems to have a higher potency for GPR55 than for either CB1 or CB2. Employing calcium mobilization assays, several groups have demonstrated anandamide-induced GPR55 activation in HEK293 cells at a concentration of 5 μM and in EA.hy926 cells (EC_{50} = 7.3 μM), suggesting lower or similar potency to that reported for anandamide at CB1 and CB2 receptors (Lauckner et al., 2008; Waldeck-Weiermair et al., 2008). Henstridge et al. (2009) have also reported calcium oscillations in response to anandamide treatment in GPR55-expressing HEK293 cells. However, they could not demonstrate specificity for GPR55 because similar oscillations were seen in untransfected control cells. In contrast, three groups have reported that anandamide did not increase ERK1/2 phosphorylation via GPR55 in either HEK293 or U2OS cells (Oka et al., 2007, 2009; Lauckner et al., 2008; Kapur et al., 2009), whereas Waldeck-Weiermair et al. (2008) did observe ERK1/2 phosphorylation at 10 μM in EA.hy926 cells. Several groups have also used β-arrestin and internalization assays to assess the properties of anandamide at GPR55. Although Yin et al. (2009) reported weak agonist activity by anandamide, Kapur et al. (2009) found no evidence of anandamide dependent β-arrestin recruitment or of GPR55 receptor internalization. At 1 μM, anandamide was shown to activate RhoA in a GPR55-dependent manner in transfected HEK293 cells (Ryberg et al., 2007), whereas Waldeck-Weiermair et al. (2008) have demonstrated nuclear factor of activated T-cell activation using 10 μM anandamide in GPR55-expressing EA.hy926 cells.

3. 2-Arachidonoyl Glycerol. The endocannabinoid ligand 2-AG (section II.C.1) binds to both CB1 and CB2 receptors with slightly greater affinity for CB1 than for CB2 (Table 1). 2-AG has been reported to be a 3 nM agonist of GPR55 in HEK293 cells using [^{35}S]GTP_{S} binding as the assay (Ryberg et al., 2007). However, in contrast to anandamide, no effect on calcium mobilization by 2-AG at 5 μM was seen in HEK293 cells (Lauckner et al., 2008). Henstridge et al. (2009) reported calcium oscillations in the presence of 3 to 30 μM 2-AG in GPR55-transfected HEK293 cells but could not demonstrate specific involvement of GPR55. 2-AG did not increase ERK1/2 phosphorylation in GPR55-expressing HEK293 or U2OS cells. In addition, 2-AG did not affect either β-arrestin recruitment

**TABLE 2**

<table>
<thead>
<tr>
<th>Ligand</th>
<th>[^35]S GTP_S Binding</th>
<th>ERK12 Phosphorylation</th>
<th>[Ca^{2+}]_i Mobilization</th>
<th>β-Arrestin</th>
<th>GPR55 Internalization</th>
<th>RhoA Activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>LPI</td>
<td>EC_{50} = 1 μM^{a}</td>
<td>EC_{50} = 200 nM^{a}</td>
<td>30 nM^{d}</td>
<td>EC_{50} = 3.6 μM^{d}</td>
<td>3 μM^{c}</td>
<td>1 μM^{d}</td>
</tr>
<tr>
<td>Anandamide</td>
<td>EC_{50} = 18 nM^{b}</td>
<td>10 μM^{d}</td>
<td>1 μM^{d,e}</td>
<td>N.E.^{e}</td>
<td>N.E.^{e}</td>
<td>N.E.^{e}</td>
</tr>
<tr>
<td>2-AG</td>
<td>EC_{50} = 3 nM^{a}</td>
<td>N.E.^{a,c}</td>
<td>N.E.^{b,c}</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
</tr>
<tr>
<td>Δ9-THC</td>
<td>EC_{50} = 8 nM^{a}</td>
<td>N.E.^{a}</td>
<td>5 μM^{b,d}</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>5 μM^{j}</td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>IC_{50} = 350 nM^{a}</td>
<td>1 μM antagonist^{d}</td>
<td>N.E.^{b}</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>1–10 μM antagonist^{d,k}</td>
</tr>
<tr>
<td>Abn-CBD</td>
<td>EC_{50} = 2.5 μM^{a}</td>
<td>N.E.^{d}</td>
<td>10 μM^{e}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
<td>N.T.</td>
</tr>
<tr>
<td>O-1602</td>
<td>EC_{50} = 13 nM^{a}</td>
<td>1 μM^{d}</td>
<td>10 μM^{d}</td>
<td>N.E.^{c}</td>
<td>1 μM^{d}</td>
<td>N.T.</td>
</tr>
<tr>
<td>CP55940</td>
<td>EC_{50} = 5 μM^{a}</td>
<td>1 μM antagonist^{d}</td>
<td>1 μM antagonist^{d} \eq^h</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
</tr>
<tr>
<td>Rimonabant</td>
<td>EC_{50} = 39 nM^{a}</td>
<td>N.T.</td>
<td>N.T.</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
</tr>
<tr>
<td>AM251</td>
<td>EC_{50} = 30 nM^{a}</td>
<td>N.T.</td>
<td>N.T.</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
</tr>
<tr>
<td>AM281</td>
<td>EC_{50} &gt; 30 μM^{a}</td>
<td>N.T.</td>
<td>N.T.</td>
<td>N.E.^{c}</td>
<td>N.E.^{c}</td>
<td>N.T.</td>
</tr>
</tbody>
</table>

N.E., no effect; N.T., not tested.

^{a} Oka et al. (2007): hGPR55 stably transfected in HEK293 cells with a tetracycline-inducible promoter.

^{b} Yin et al. (2009): hGPR55 transiently transfected in HEK293 cells.

^{c} Kapur et al. (2009): hGPR55 stably transfected in HEK293 cells (β-arrestin assay) or U2OS cells (β-arrestin and GPR55 internalization assays).

^{d} Whyte et al. (2009): human osteoclast primary cultures.

^{e} Whyte et al. (2009): mouse osteoclast primary cultures.

^{f} Pietr et al. (2009): BV-2 (mouse microglial cell line).

^{g} Lauckner et al. (2008): hGPR55 transiently transfected in HEK293 cells.

^{h} Lauckner et al. (2008): mouse DRG primary cultures.

^{i} Henstridge et al. (2009): hGPR55 stably transfected in HEK293 cells.

^{j} Waldeck-Weiermair et al. (2008): EA.hy926 (human umbilical vein derived endothelial cell line).

^{k} Ryberg et al. (2007): hGPR55 transiently transfected in HEK293 cells.

^{l} Johns et al. (2007): hGPR55 transiently transfected in HEK293 cells.
or GPR55 receptor internalization (Kapur et al., 2009; Yin et al., 2009).

4. Lysophosphatidyl Inositol. LPI has consistently been shown to be an agonist of GPR55. Thus, LPI (1 μM) can stimulate \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding to GPR55-expressing cell membranes (Oka et al., 2007) and has also been found to activate ERK1/2 in GPR55-transfected HEK293 cells with an EC\(_{50}\) of 200 nM as well as in GPR55-expressing U2OS cells and in human osteoclasts when tested at 10 and 1 μM, respectively (Oka et al., 2007; Kapur et al., 2009; Whyte et al., 2009). Apparent GPR55-mediated calcium mobilization by LPI has been reported in EA.hy926 cells at 10 μM (Waldeck-Weiermair et al., 2008), in mouse dorsal root ganglia at 3 μM (Lauckner et al., 2008), and in HEK293 cells with EC\(_{50}\) values of 30 and 49 nM (Oka et al., 2007; Henstridge et al., 2009). When using either β-arrestin recruitment or GPR55 receptor internalization assays, LPI was active as an apparent GPR55 agonist between 1 to 3 μM (Henstridge et al., 2009; Kapur et al., 2009; Yin et al., 2009). LPI has also been reported to induce GPR55-mediated activation of RhoA in transfected HEK293 cells (Henstridge et al., 2009), as well as in human and mouse osteoclasts (Whyte et al., 2009). Evidence has also recently emerged that the endogenous compound, 2-arachidonoyl lysophosphatidyl inositol, activates GPR55 more potently than LPI in HEK293 cells and, hence, that this ligand may be the true intrinsic natural ligand for GPR55 (Oka et al., 2009).

5. \(\Delta^9\)-Tetrahydrocannabinol. The principal psychoactive component of the cannabis plant, \(\Delta^9\)-THC (section II.C.1), binds equally well to cannabinoid CB\(_1\) and CB\(_2\) receptors (Table 1). This cannabinoid has been reported to display significant potency as an agonist at GPR55 with an EC\(_{50}\) of 8 nM in a \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding assay performed with HEK293 cells (Ryberg et al., 2007). Using 5 μM \(\Delta^9\)-THC, Lauckner et al. (2008) reported a modest increase in intracellular calcium in both mouse and human GPR55-expressing HEK293 cells as well as in mouse dorsal root ganglia. In contrast, using GPR55 internalization and β-arrestin recruitment assays, Kapur et al. (2009) detected no sign of \(\Delta^9\)-THC-induced activation of GPR55, whereas Yin et al. (2009) reported very weak GPR55-mediated β-arrestin recruitment in response to this ligand.

6. Abnormal-Cannabidiol. Abnormal-cannabidiol (abn-CBD; section II.C.5 and Fig. 5) lacks significant affinity for CB\(_1\) and CB\(_2\) receptors but has been reported to have a number of in vivo effects through one or more as yet undefined receptors (section III.H.2). Both Johns et al. (2007) and Ryberg et al. (2007) have reported \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding data for this ligand at GPR55 expressed in HEK293 cells, albeit indicating 1000-fold different potencies (EC\(_{50}\) = 2.5 nM and 2.5 μM, respectively). No effect of this ligand on GPR55-mediated ERK1/2 activation was seen at a concentration of 1 μM (Oka et al., 2007) and no abn-CBD–induced GPR55-mediated mobilization of calcium was observed at 3 μM (Lauckner et al., 2008). Furthermore, no GPR55-mediated activity of abn-CBD was seen when this ligand was tested in β-arrestin recruitment assays (Kapur et al., 2009; Yin et al., 2009).

7. Cannabidiol. The phytocannabinoid cannabidiol (section II.C.5), which has therapeutic potential as an anti-inflammatory agent, displays relatively low affinity for CB\(_1\) and CB\(_2\) receptors (Table 1). Ryberg et al. (2007) demonstrated that cannabidiol could antagonize the stimulation of \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding by anandamide, CP55940, and O-1602 in GPR55-transfected HEK293 cells with an IC\(_{50}\) of 350 nM. No confirmatory data from other laboratories are available using cannabidiol as an antagonist in transfected cells. However, Whyte et al. (2009) have reported that cannabidiol displays GPR55 antagonist activity in human osteoclasts at 1 μM using ERK1/2 phosphorylation and RhoA activation assays. Cannabidiol had no GPR55 agonist activity when assayed in calcium mobilization assays at 3 μM or when tested in β-arrestin recruitment assays (Kapur et al., 2009; Yin et al., 2009). Collectively, these data demonstrate that cannabidiol is an antagonist of GPR55.

8. O-1602. O-1602 is an analog of abn-CBD in which the pentyl group has been replaced by a methyl group (section II.C.5 and Fig. 5). O-1602 has been reported to have activity at a non-CB\(_1\)/CB\(_2\) receptor in the vasculature, the putative abnormal-cannabidiol receptor (section III.H.2). Using \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding assays, two independent groups have reported nanomolar activity of this compound at GPR55 expressed in HEK293 cells. Ryberg et al. (2007) determined an EC\(_{50}\) of 13 nM, whereas Johns et al. (2007) found an EC\(_{50}\) of 1.4 nM. O-1602 has been shown to promote apparent GPR55-mediated ERK1/2 phosphorylation in human osteoclasts as well as RhoA activation at 1 μM in HEK293 cells and in human and mouse osteoclasts. Oka et al. (2007) reported no effect of O-1602 on calcium mobilization in GPR55-transfected HEK293 cells at 1 μM, whereas Waldeck-Weiermair et al. (2008) did see a calcium signal in GPR55-expressing EA.hy926 cells in response to this compound at 10 μM. Collectively, these data support O-1602 as an agonist of GPR55, coupling signaling via G protein activation to RhoA. Using β-arrestin recruitment assays, however, neither Yin et al. (2009) nor Kapur et al. (2009) observed any activity for O-1602 at GPR55.

9. CP55940. The potent cannabinoid receptor agonist CP55940 (section II.C.1) has high affinity for both CB\(_1\) and CB\(_2\) receptors (Table 1) and is widely used in cannabinoid research as a pharmacological tool. Using a \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding assay, a potency (EC\(_{50}\) = 5 nM) similar to its potency as a CB\(_1\) and CB\(_2\) receptor agonist has been demonstrated for CP55940 at GPR55 (Ryberg et al., 2007). Unfortunately, no confirmatory \(^{35}\)S\(\text{GTP}\gamma\text{S}\) binding data are available from other groups. However, this ligand has been investigated in other assays. Alone, CP55940 failed to demonstrate any agonist activity in either ERK1/2 activation (Oka et al., 2007) or calcium mobilization GPR55...
assays (Lauckner et al., 2008), although it did not antagonize apparent GPR55-mediated ERK1/2 phosphorylation at a concentration of 10 μM (Kapur et al., 2009).

10. R(+)-WIN55212. R(+)-WIN55212 (section II.C.1 and Table 1) is a potent, nonselective CB1 and CB2 receptor agonist that has been used in many studies of cannabinoid receptor function. The available data for R(+)-WIN55212 activity at GPR55 are highly consistent, most laboratories finding no effect of this cannabinoid on any of the GPR55 assay end points used (Oka et al., 2007; Ryberg et al., 2007; Lauckner et al., 2008; Kapur et al., 2009).

11. Rimonabant. Rimonabant (section II.C.3. and Table 1) is a potent CB1 receptor antagonist that was developed as an antiobesity agent. No [35S]GTPγS binding data on this compound at GPR55 have been published. However, signs of GPR55 antagonism have been detected at 1 μM in EA.hy926 cells and at 2 μM in HEK293 cells and mouse dorsal root ganglia using calcium mobilization assays (Lauckner et al., 2008; Waldeck-Weiermair et al., 2008). In contrast, Henstridge et al. (2010) reported agonist activity for rimonabant in the range of 10 nM to 3 μM, as indicated by elevations of intracellular calcium in GPR55-expressing HEK293 cells. GPR55 agonist activity by rimonabant is also reported for β-arrestin recruitment with EC50 values of 9.3 and 3.9 μM (Kapur et al., 2009; Yin et al., 2009). Likewise, Kapur et al. (2009) have reported receptor internalization at 30 μM rimonabant in GPR55-expressing HEK293 and U2OS cells, consistent with the findings of Henstridge et al. (2010) that this compound can act as a GPR55 agonist. In addition, Henstridge et al. (2010) demonstrated that rimonabant activates ERK1/2, cAMP response element-binding protein phosphorylation, and nuclear factor κ-light-chain-enhancer of activated B cells via GPR55 and also that it induces GPR55 internalization.

12. AM251. Like rimonabant, AM251 (section II.C.3 and Table 1) is a potent CB1 receptor antagonist. It has been shown in a [35S]GTPγS binding assay using transfected HEK293 cells to be a high-potency agonist of GPR55 (EC50 = 39 nM) (Ryberg et al., 2007). Henstridge et al. (2009) have reported an EC50 of 612 nM for calcium mobilization in GPR55-expressing HEK293 cells. AM251 promotes β-arrestin recruitment with EC50 values of 3 and 9.6 μM (Kapur et al., 2009; Yin et al., 2009) and GPR55 internalization (Kapur et al., 2009; Henstridge et al., 2010).

13. Other Ligands. Using a [35S]GTPγS binding assay, Ryberg et al. (2007) found that hGPR55 stably transfected into HEK293 cells was activated by nanomolar concentrations of the following lipids: noladin ether (section II.C.2 and Table 1) and virodhamine (section II.C.5 and Table 1), both of which are cannabinoid receptor agonists, and the non-CB1/CB2 receptor ligands, oleoyl ethanolamide and palmitoyl ethanolamide. Palmitoyl ethanolamide, which is of interest because of its potent anti-inflammatory, antiexcitotoxic, and antiinflammatory properties (Skaper et al., 1996; Jaggar et al., 1998), also displays significant potency as a PPARα agonist (section III.G). It was originally thought to be an endogenous ligand for the CB2 receptor (Facci et al., 1995). However, subsequent studies showed it to have little affinity for this receptor (Showalter et al., 1996; Griffin et al., 2000).

14. Impact of Cell Lines and Expression Levels on GPR55 Data. It is well known that cell lines present inconsistent phenotypes over time. For example, Dubi et al. (2008) have recently demonstrated that the androgen-insensitive PC-3 cell line exhibited two sublines that showed distinct receptor activation. The clonal background of HEK293 cells can differ markedly between laboratories. It is noteworthy, therefore, that GPR55 experiments were carried out by Ryberg et al. (2007) with a HEK293s cell line and by Johns et al. (2007) with a HEK293T cell line, and also, that these and other investigations into the ability of cannabinoid receptor ligands to target GPR55 (Oka et al., 2007; Lauckner et al., 2008; Henstridge et al., 2009; Kapur et al., 2009) were each performed in a different laboratory. It is noteworthy, too, although HEK293 cells are referred to as “human embryonic kidney” cells, a study on the origin of this cell line suggests that these cells may in fact have been derived by adenoviral transformation of a neuronal precursor present in the HEK cell cultures from which the original HEK293 cell line was obtained (Shaw et al., 2002).

Many in vitro studies of GPR55 have used transfected cells overexpressing this receptor (Johns et al., 2007; Ryberg et al., 2007; Lauckner et al., 2008; Kapur et al., 2009). If overexpression of the receptor induces constitutive activity, this can lead to altered ligand behavior (Kenakin, 2001). Moreover, because of cell line and tissue heterogeneity, there may be accessory and other proteins in the various cell lines that modify the response of GPR55. The change in anandamide-induced CB2/GPR55 signaling that seems to occur in endothelial cells because of integrin clustering is one published example (Waldeck-Weiermair et al., 2008). The manner in which GPR55 responds to its ligands may also be dependent on cell culture conditions. Moreover, HEK293 and other cells can synthesize lipid mediators, and this may alter the measured response (Turu et al., 2009). The presence of endocannabinoids in serum has also been documented (Valk et al., 1997), and other growth factors are present as well.

15. Conclusions. Because of the large body of conflicting pharmacological data, no conclusive decision can yet be reached about whether GPR55 should be classified as a novel cannabinoid receptor. Particularly noteworthy are the mixed findings that have been obtained with the endocannabinoid anandamide. Thus, this compound has been found in GPR55 assays to stimulate [35S]GTPγS binding in the nanomolar range, to cause calcium mobilization in the micromolar range, but not to affect ERK1/2 phosphorylation or β-arrestin recruitment or to induce GPR55 internalization. These mixed findings may be the product of biased agonism at GPR55 or may have resulted simply from the use of different assay end points and cell systems. Therefore, although anandamide has been shown to be active at GPR55 in certain assays and cell types, the inconsistent manner with
which it has been found to interact with this receptor prevents unequivocal designation of anandamide as a GPR55 ligand. Whether this inconsistency is the result of biased agonism or experimental variation remains to be determined; until it is, GPR55 cannot be considered an anandamide receptor.

The data for 2-AG are more consistent, albeit mainly negative. Thus, although it has been shown to display activity as a GPR55 agonist in a [35S]GTPγS binding assay, the majority of studies using calcium mobilization, ERK1/2 phosphorylation, or β-arrestin recruitment and receptor internalization have failed to demonstrate any effect of this endocannabinoid on GPR55. Consequently, there is no conclusive evidence at this time that this endocannabinoid is a ligand of GPR55. As for Δ9-THC, although it displays activity as a GPR55 agonist in [35S]GTPγS binding, calcium mobilization, and RhoA activation assays, it fails to stimulate ERK1/2 phosphorylation, β-arrestin recruitment, or GPR55 internalization. Whether this is a result of biased agonism by Δ9-THC or experimental variability remains to be determined.

A rare consensus among the articles published on GPR55 is that LPI is an agonist for this receptor. Another agreement among published reports is that the aminoalkylindole R(+)-WIN555212, a potent CB1 and CB2 receptor agonist, does not target GPR55 as either an agonist or an antagonist. In contrast, both CP55940 and rimonabant have been found to behave as GPR55 agonists in some investigations but as GPR55 antagonists in others, possibly an indication that they possess low relative intrinsic activity as GPR55 agonists, although this remains to be established. Finally, the finding that 2-arachidonoyl lysophosphatidyl inositol is an endogenous agonist for GPR55 (section III.A.4) has revealed an interesting “parallel” between the chemical nature of GPR55 and CB1/CB2 receptor endogenous ligands.

B. Other Deorphanized G Protein-Coupled Receptors

1. GPR40, GPR41, GPR42, and GPR43. In 2003, it was discovered by three different research groups that the receptor GPR40 can be activated by long- and medium-chain fatty acids (C6-C22; Table 3) (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003). The receptor has been renamed FFA1 because it is now thought to be a fatty acid receptor that is involved in the regulation of insulin release (Stoddart et al., 2008). That GPR40 is indeed a fatty acid receptor has been confirmed in a recent investigation that used a new β-arrestin assay to deorphanize G protein-coupled receptors (Yin et al., 2009). FFA1 can be activated by glitazone drugs that are activators of PPARγ (Kotarsky et al., 2003; Gras et al., 2009; Smith et al., 2009), and a number of other small-molecule agonists/antagonists for FFA1 have also been discovered (Bharate et al., 2009; Hara et al., 2009; Hu et al., 2009). However, FFA1 has not been reported to be activated or inhibited by any known cannabinoid CB1 or CB2 receptor agonist or antagonist.

In the same year, two other orphan receptors, GPR41 and GPR43, were identified by three independent research groups as receptors for short-chain fatty acids (C1-C6; Table 3) (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003) and these receptors have now been renamed FFA3 and FFA2, respectively (Stoddart et al., 2008). FFA2 is found in adipose tissue, where its activation may increase leptin production and, in white blood cells, where it may stimulate chemotaxis. FFA3 is found on immune cells, in the gastrointestinal tract, and in adipose tissue. FFA2 knockout mice do not respond to acetate-induced reductions in plasma free fatty acid levels, indicating a role for this receptor in the stimulation of lipolysis. A series of small molecule phenylacetamides have been found to be more potent FFA2 agonists, and these may also act as allosteric ligands at an allosteric binding site on FFA2 (Lee et al., 2008). FFA2 and FFA3 have not been reported to be activated or inhibited by any known agonists or antagonists for cannabinoid CB1 or CB2 receptors.

The GPR42 gene codes for a GPR42 receptor that is very similar to FFA3 but cannot be activated by short-chain fatty acids, prompting the suggestion that it is a pseudogene (Brown et al., 2003). However, recent findings suggest that GPR42 could potentially be a functional gene in a fraction of the human population because of a polymorphism resulting in the presence of arginine at amino acid 174 of the receptor (Liaw and Smith et al., 2009). FFA1 can be activated by glitazone drugs that are activators of PPARγ (Kotarsky et al., 2003; Gras et al., 2009; Smith et al., 2009), and a number of other small-molecule agonists/antagonists for FFA1 have also been discovered (Bharate et al., 2009; Hara et al., 2009; Hu et al., 2009). However, FFA1 has not been reported to be activated or inhibited by any known cannabinoid CB1 or CB2 receptor agonist or antagonist.

In the same year, two other orphan receptors, GPR41 and GPR43, were identified by three independent research groups as receptors for short-chain fatty acids (C1-C6; Table 3) (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003) and these receptors have now been renamed FFA3 and FFA2, respectively (Stoddart et al., 2008). FFA2 is found in adipose tissue, where its activation may increase leptin production and, in white blood cells, where it may stimulate chemotaxis. FFA3 is found on immune cells, in the gastrointestinal tract, and in adipose tissue. FFA2 knockout mice do not respond to acetate-induced reductions in plasma free fatty acid levels, indicating a role for this receptor in the stimulation of lipolysis. A series of small molecule phenylacetamides have been found to be more potent FFA2 agonists, and these may also act as allosteric ligands at an allosteric binding site on FFA2 (Lee et al., 2008). FFA2 and FFA3 have not been reported to be activated or inhibited by any known agonists or antagonists for cannabinoid CB1 or CB2 receptors.

The GPR42 gene codes for a GPR42 receptor that is very similar to FFA3 but cannot be activated by short-chain fatty acids, prompting the suggestion that it is a pseudogene (Brown et al., 2003). However, recent findings suggest that GPR42 could potentially be a functional gene in a fraction of the human population because of a polymorphism resulting in the presence of arginine at amino acid 174 of the receptor (Liaw and

---

**TABLE 3**

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Recognized Agonist(s)</th>
<th>EC50 Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFA1 (GPR40)</td>
<td>Fatty acids (C6-C22)</td>
<td>Micromolar</td>
</tr>
<tr>
<td>FFA2 (GPR41)</td>
<td>Fatty acids (C1-C6)</td>
<td>Micromolar to millimolar</td>
</tr>
<tr>
<td>GPR44</td>
<td>Fatty acids (C9-C14)</td>
<td>Micromolar</td>
</tr>
<tr>
<td>GPR120</td>
<td>Fatty acids (C14-C22)</td>
<td>Micromolar</td>
</tr>
<tr>
<td>GPR3</td>
<td>Sphingosine-1-phosphate?</td>
<td>Micromolar</td>
</tr>
<tr>
<td>GPR6</td>
<td>Sphingosine-1-phosphate?</td>
<td>Micromolar</td>
</tr>
<tr>
<td>GPR12</td>
<td>Sphingosylphosphorylcholine?</td>
<td>Nanomolar to micromolar</td>
</tr>
<tr>
<td>GPR18</td>
<td>LPA</td>
<td>Nanomolar to micromolar</td>
</tr>
<tr>
<td>GPR23</td>
<td>LPA*</td>
<td>Nanomolar to micromolar</td>
</tr>
<tr>
<td>GPR119</td>
<td>OEA/OLDA</td>
<td>Low micromolar</td>
</tr>
</tbody>
</table>

OEA, oleoyl ethanolamide; OLDA, N-oleoyl dopamine.
Connolly, 2009). If that is the case, it is likely that an active GPR42 will have nearly the same properties as the FAAH receptor.

2. GPR84 and GPR120. The two orphan receptors, GPR84 and GPR120, seem to be receptors for medium-chain fatty acids (C9-C14; Table 3) (Wang et al., 2006a) and for long-chain fatty acids (C14-C22) (Hirasawa et al., 2005; Katsuma et al., 2005), respectively.

GPR84 is highly expressed in bone marrow, and in splenic T cells and B cells, and results from studies with GPR84 knockou mice suggest that GPR84 is involved in regulating early IL-4 gene expression in activated T cells (Venkataraman and Kuo, 2005) and that it is expressed in activated microglial cells and macrophages (Bouchard et al., 2007; Lattin et al., 2008). Medium-chain fatty acids activate GPR84 as can be seen from their ability to decrease intracellular cAMP and to stimulate [35S]GTPγS binding to membranes from CHO cells stably expressing GPR84 (Wang et al., 2006a). Short- and long-chain fatty acids were inactive, and GPR84 has not been reported to be activated or inhibited by any known agonists or antagonists for cannabinoid CB₁ or CB₂ receptors.

GPR120 is found mainly in the intestinal tract, although it is also expressed by a number of other tissues (e.g., adipocytes, taste buds, and lung) (Ichimura et al., 2009). More specifically, intestinal GPR120 is found in glucagon-like peptide-1 (GLP-1)-expressing endocrine cells in the large intestine (Hirasawa et al., 2005; Miyauuchi et al., 2009) and in gastric inhibitory polypeptide-expressing K cells of the duodenum and jejunum (Parker et al., 2009). Dietary fatty acids may promote intestinal CCK and GLP-1 release via activation of intestinal GPR120 (Tanaka et al., 2008; Ichimura et al., 2009). Long-chain fatty acids (C14–C22; Table 3), especially unsaturated ones, activate GPR120 in cell lines stably expressing this receptor, as measured by an increase in intracellular Ca²⁺, whereas α-linolenic acid methyl ester lacks activity (Hirasawa et al., 2005). It is noteworthy that some plant-derived compounds, grifolin derivatives that do not contain a carboxylic group, can also activate GPR120 (Hara et al., 2009). GPR120 has not been reported to be activated or inhibited by any known agonists or antagonists for cannabinoid CB₁ or CB₂ receptors.

3. GPR3, GPR6, and GPR12. GPR3, GPR6, and GPR12 are constitutively active proteins that signal through Gαₛ to increase cAMP levels in cells expressing these receptors (Tanaka et al., 2007). They are mainly expressed in the central nervous system, where they may contribute to the regulation of neuronal proliferation (Tanaka et al., 2009), monoamine neurotransmission (Valverde et al., 2009), reward learning processes (Lobo et al., 2007), and energy expenditure (Bjursell et al., 2006). They may also be involved in the regulation of meiosis in oocytes (Hinckley et al., 2005). Their closest phylogenetic GPCR relatives are cannabinoid receptors, lysophospholipid receptors, and melanocortin receptors (Uhlenbrock et al., 2002).

It has been suggested that GPR3, GPR6, and GPR12 (Table 3) are all activated by sphingosine-1-phosphate and/or sphingosylphosphorylcholine at nanomolar concentrations (Uhlenbrock et al., 2002; Ignatov et al., 2003a,b; Lobo et al., 2007). Results obtained in a recent investigation using β-arrestin recruitment instead of G protein activation as an assay for receptor agonism do, however, challenge this hypothesis as no sign of agonism was seen in response to sphingosine-1-phosphate or sphingosylphosphorylcholine at 8 and 42 μM, respectively (Yin et al., 2009). A large number of endogenous lipids, including endocannabinoids, were screened in this investigation and none of these were found to activate GPR3, GPR6, or GPR12 (Yin et al., 2009). However, anandamide and 2-AG did show weak agonist activity at the S1P₁ receptor (edg1) at concentrations in the micromolar range (Yin et al., 2009).

4. GPR18 and GPR92. The chromosomal location of GPR18 has been determined as 13q32.3; it is a 331-amino acid GPCR. GPR18 (Table 3) is highly expressed in spleen, thymus, and peripheral lymphocyte subsets (Gantz et al., 1997; Kohno et al., 2006). In GPR18-transfected cells, N-arachidonoyl glycine (NAGly) has been shown to induce intracellular Ca²⁺ mobilization at 10 μM (Kohno et al., 2006). Furthermore, the same study demonstrated inhibition of forskolin-stimulated cAMP production by NAGly with an EC₅₀ of 20 nM; the effect was absent in untransfected cells and was pertussis toxin-sensitive, suggesting Gₛ-coupling. A more recent study used the β-arrestin PathHunter assay system to examine the pharmacological interactions of various lipids with a range of recently deorphanized GPCRs (Yin et al., 2009). In this study, NAGly did not activate GPR18 but elicited a weak activation of GPR92, at concentrations above 10 μM. GPR92 mRNA is highly expressed in dorsal root ganglia, suggesting a role in sensory neuron transmission. Oh et al. (2008) have also demonstrated that NAGly mobilizes intracellular Ca²⁺ and activates [35S]GTPγS binding in GPR92-expressing cells. However, the relative intrinsic activity of NAGly is significantly lower than that of the other putative endogenous GPR92 agonists, LPA and farnesyl pyrophosphate (Oh et al., 2008; Williams et al., 2009). In addition, farnesyl pyrophosphate and LPA activate both Gₛ₁₁ and Gₛ-mediated signaling, whereas NAGly activates only Gₛ₁₁-mediated signaling. To date, there are no published data to indicate whether cannabinoid CB₁ or CB₂ receptor ligands can activate or block GPR18 or GPR92. It is noteworthy, however, that GPR18 may be a receptor for abnormal-cannabidiol (section III.H.2).

5. GPR23. The orphan receptor GPR23/p2y9 is closely related to the purinergic P2Y receptor and mRNA for this receptor in the mouse is mainly found in ovary, uterus, and placenta (Ishii et al., 2009). It has been found (Table 3) that GPR23 is activated by LPA in...
the nanomolar range as indicated by intracellular calcium mobilization and cAMP formation (Noguchi et al., 2003), probably through the activation of Gi/11 and Gs proteins (Ishii et al., 2009). Two other recent investigations have used β-arrestin recruitment to test the ability of LPA to activate GPR23. In one of these, activation was detected at 100 μM (Wetter et al., 2009), whereas in the other, no activation was induced by concentrations of up to 100 μM LPA (Yin et al., 2009). GPR23 has not been reported to be activated or inhibited by any known agonists or antagonists for cannabinoid CB1 or CB2 receptors.

6. GPR119. The human orphan receptor GPR119, identified by a basic local alignment search tool search of the genomic database, is an intronless GPCR belonging to the MECA (melanocortin, endothelial differentiation gene, cannabinoid, adenosine) cluster of receptors (Fredriksson et al., 2003a). It is preferentially expressed in pancreatic and intestinal cells, where it is involved in the control of glucose-dependent insulin release and GLP-1 release, respectively (Soga et al., 2005; Chu et al., 2007; Lauffer et al., 2008). Although GPR119 is phylogenetically related to cannabinoid receptors, only fatty acid amides interact with GPR119 (Table 3), the potency order of four of these being N-oleyl dopamine > oleoyl ethanolamide > palmitoyl ethanolamide > anandamide (Overyton et al., 2006; Chu et al., 2010). Because only N-oleyl dopamine and oleoyl ethanolamide have reasonably high (low micromolar) affinity for GPR119, and because neither of these lipids interacts with CB1 or CB2 receptors, GPR119 cannot be viewed as a cannabinoid receptor. Oleoyl ethanolamide also activates TRPV1 channels and PPARs (sections III.E and III.G).

7. Conclusions. There is evidence that at least some cannabinoid receptor agonists do not activate GPR119, GPR3, GPR6, or GPR12 with significant potency (Table 3 and sections III.B3 and III.B.6). However, to our knowledge, cannabinoids have not been tested as ligands for most of the receptors mentioned in Table 3 or, in any case, no such data have been published. Clearly, therefore, there is a need for the receptors listed in Table 3 to be tested for their responsiveness to a broad spectrum of potential ligands, including a carefully selected range of cannabinoids, to help clarify their pharmacological profiles and physiological roles and so provide a conclusive deorphanization of these receptors.

C. Established G Protein-Coupled Receptors

At concentrations in the low micromolar range, some cannabinoid receptor agonists (Table 4) or antagonists seem to target certain G protein-coupled “noncannabinoid” receptors, in some instances probably by targeting allosteric sites on these receptors. These G protein-coupled receptors include muscarinic acetylcholine receptors and α2- and β-adrenoceptors and also opioid, adenosine, 5-HT, angiotensin, prostanoid, dopamine, melatonin, and tachykinin receptors.

1. Opioid Receptors. There is evidence that certain phytocannabinoids or synthetic cannabinoids can act allosterically at concentrations in the low micromolar range to accelerate the dissociation of ligands from the orthosteric sites on µ- and/or δ-opioid receptors. Thus, it has been found that the rate of dissociation of [3H]DAMGO ([3H][D-Ala²,N-Me-Phe⁴,Gly⁵-ol]-enkephalin), presumably from µ-opioid receptors, and of [3H]naltrindol, presumably from δ-opioid receptors, can be increased by Δ⁹-THC (EC₅₀ = 21.4 and 10 μM, respectively) (Kathmann et al., 2006). In contrast, rimonabant seems to displace [3H]DAMGO in a competitive manner (IC₅₀ = 4.1 μM). Results obtained from equilibrium binding experiments with rat whole-brain membranes also suggest that Δ⁹-THC is a noncompetitive inhibitor of ligand binding to µ- and δ-opioid receptors (IC₅₀ = 7 and 16 μM, respectively), although not to κ-opioid receptors or σ/phencyclidine receptors, and that inhibition of ligand binding to µ-opioid receptors can be induced by certain other cannabinoids (Vaysse et al., 1987). In addition, it has been found by both Fong et al. (2009) and Cinar and Szucs (2009) that rimonabant can induce radioligand displacement from µ-opioid receptors (IC₅₀ = 3 and 5.7 μM, respectively), and by Fong et al.

Table 4

<table>
<thead>
<tr>
<th>Receptor and Effect</th>
<th>Endocannabinoid(s)†?</th>
<th>Effective Concentration Range</th>
<th>Nonendogenous Cannabinoid Agonists‡?</th>
<th>Effective Concentration Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radioligand binding (</td>
<td>)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioid (µ- and δ-)</td>
<td>N.D.</td>
<td>N.D.</td>
<td>Yes*</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Acetylcholine (muscarinic)</td>
<td>Yes* b</td>
<td>Micromolar</td>
<td>Yes* c</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Adrenosine A₁</td>
<td>Yes*</td>
<td>Micromolar</td>
<td>Yes*</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Adrenosine A₂</td>
<td>Yes*</td>
<td>Micromolar</td>
<td>Yes*</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Angiotensin 1-2</td>
<td>Yes*</td>
<td>Micromolar</td>
<td>Yes*</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Radioligand binding (</td>
<td>)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetylcholine (muscarinic)</td>
<td>Yes* b</td>
<td>Micromolar</td>
<td>Yes* c</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Adrenosine (β-)</td>
<td>N.D.</td>
<td>N.D.</td>
<td>Yes*</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Adrenosineceptors (β-)</td>
<td>No</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
</tbody>
</table>

N.D., no data.  
† May target an allosteric site on this receptor.  
‡ Also R(−)-methanandamide.  
§ Also R(−)-methanandamide.  
b Also 5-HT₂A and 5-HT₂B.
(2009) that this CB₁ receptor antagonist can induce radioligand displacement from κ-opioid receptors (IC₅₀ = 3.9 μM).

2. Muscarinic Acetylcholine Receptors. At concentrations in the micromolar range, both anandamide and R-(+)-methanandamide have been shown to modulate tritiated ligand binding to muscarinic acetylcholine receptors, probably by targeting allosteric sites on these receptors. Thus, Legalwar et al. (1999) found that [³H]N-methylscopolamine and [³H]quinuclidinyl benzilate could be displaced from binding sites on adult human frontal cerebrocortical membranes in a noncompetitive manner by both anandamide (IC₅₀ = 44 and 50 μM, respectively) and R-(+)-methanandamide (IC₅₀ = 15 and 34 μM, respectively) but not R-(+)-WIN555212 (up to 5 μM). Both ethanolamides stimulated [³H]oxotremorine binding to these membranes at concentrations below 50 or 100 μM, although they did inhibit such binding at higher concentrations. It was concluded that these effects of anandamide did not require its conversion to arachidonic acid. It has also been found that anandamide and R-(+)-methanandamide but not R-(+)-WIN555212 can displace tritiated ligands from human M₁ and M₄ muscarinic acetylcholine receptors transfected into CHO cells (Christopoulos and Wilson, 2001). IC₅₀ values for the displacement of [³H]N-methylscopolamine and [³H]quinuclidinyl benzilate from M₁ receptors were 2.8 and 13.5 μM, respectively, for anandamide and 1.45 and 6.5 μM, respectively, for R-(+)-methanandamide. Corresponding IC₅₀ values for the displacement of these tritiated ligands from M₄ receptors were 8.3 and 6.9 μM for anandamide and 9.8 and 3.1 μM for R-(+)-methanandamide. The effect of anandamide on tritiated ligand binding seemed to be noncompetitive and hence possibly allosteric in nature. It is noteworthy, however, that anandamide (10 μM) was subsequently found by the same research group not to affect the rate of dissociation of [³H]N-methylscopolamine from M₁ binding sites (Lanzafame et al., 2004).

3. Other Established G Protein-Coupled Receptors. It has been reported that at 10 μM, both rimonabant and AM251 can oppose the activation of adenosine A₁ receptors in rat cerebellar membranes and that these CB₁ receptor antagonists can inhibit basal [³⁵S]GTPyS binding to these membranes, probably by blocking A₁ receptor activation by endogenously released adenosine (Savinainen et al., 2003). In addition, evidence has been obtained, first, that at 10 μM, both anandamide and 2-AG, but not AM251, R-(+)-WIN555212, or CP55940 can act as allosteric inhibitors at the human adenosine A₃ receptor although not at the human adenosine A₁ receptor (Lane et al., 2010), and second, that both rimonabant (IC₅₀ = 1.5 μM) and taranabant (IC₅₀ = 3.4 μM) can induce radiolabeled ligand displacement from adenosine A₃ receptors (Fong et al., 2009). In contrast to taranabant (IC₅₀ > 10 μM), rimonabant can also displace radiolabeled ligands from α₂A and α₂C-adrenoceptors, from 5-HT₆ and angiotensin AT₁ receptors, and from prostanoid EP₄, FP, and IP receptors with IC₅₀ values ranging from 2 to 7.2 μM (Fong et al., 2009). Taranabant, however, has been found to displace radiolabeled ligands from dopamine D₁ and D₃ receptors (Kᵢ = 3.4 and 1.9 μM, respectively) and from melatonin MT₁ receptors (Kᵢ = 5.4 μM) (Fong et al., 2007). In addition, both rimonabant (IC₅₀ = 2 μM) and taranabant (IC₅₀ = 0.5 μM) can induce radiolabeled ligand displacement from tachykinin NK₂ receptors (Fong et al., 2009).

There is also evidence that at 3 or 10 μM, but not higher or lower concentrations, both Δ⁹-THC and 11-hydroxy-Δ⁸-THC increase the affinity of [³H]dihydroalprenolol for β-adrenoceptors in mouse cerebral cortical membranes (Hillard and Bloom, 1982). There is evidence too that [³H]5-HT binding to 5-HT₁A, 5-HT₁B, 5-HT₁D, 5-HT₁E, and/or 5-HT₂C receptors in bovine cerebral cortical synaptic membranes can be reduced by 11-hydroxy-Δ⁸-THC and 11-oxo-Δ⁸-THC although not Δ⁸-THC at 10 μM, and by anandamide at 1 and 10 μM (Kimura et al., 1996, 1998). The same concentrations of these cannabinoids did not decrease [³H]ketanserin binding to 5-HT₂A or 5-HT₂B receptors, although evidence was obtained that anandamide can reduce radioligand binding to 5-HT₁ and 5-HT₂ receptors at 100 μM. In addition, there has been a report that [³H]ketanserin binding to 5-HT₂ receptors in rat cerebral cortical membranes is enhanced by HU-210 at 500 nM (Cheer et al., 1999).

4. Conclusions. There is evidence that at concentrations in the nanomolar or micromolar range, either or both of two CB₁ receptor antagonists/inverse agonists, rimonabant and taranabant, can bind to some types of opioid, adrenergic, dopamine, 5-HT, adenosine, angiotensin, melatonin, tachykinin, and prostanoid receptors. There is also evidence that anandamide, 2-AG, and/or certain established nonendogenous CB₁/CB₂ receptor agonists can interact with at least some types of opioid, muscarinic acetylcholine, adrenergic, 5-HT, and adenosine receptors (Table 4). However, the potency with which these ligands target these receptors is significantly less than the potency with which they activate or block CB₁ and/or CB₂ receptors. Moreover, at least some of these interactions seem to be allosteric in nature. Consequently, no convincing case can be made for reclassifying any of the receptors mentioned in this section as a novel cannabinoid receptor.

D. Ligand-Gated Ion Channels

Several cannabinoid receptor agonists have been found to antagonize or enhance the activation of 5-HT₃, nicotinic acetylcholine, glycine, and/or ionotropic glutamate (NMDA) receptors (Table 5).

1. 5-HT₃ Receptors. There has been one report that antagonism of the activation of 5-HT₃ receptors by 5-HT can be induced by CP55940, R-(+)-WIN555212, and
anandamide with IC$_{50}$ values of 94, 310, and 190 nM, respectively (Fan, 1995), and another report that these compounds induce antagonism of this kind with IC$_{50}$ values of 648, 104, and 130 nM, respectively (Barann et al., 2002). The second of these research groups also found 5-HT$_{3}$ receptor activation to be potently antagonized by two other cannabinoid receptor agonists, $\Delta^{9}$-THC and JWH-015 (IC$_{50} = 38$ and 147 nM, respectively) and by the CB$_{1}$ receptor antagonist/inverse agonist LY320135 (IC$_{50} = 523$ nM), although not by rimonabant at 1 µM. In other investigations, anandamide has been found to antagonize 5-HT$_{3}$ receptor activation with IC$_{50}$ values of 239 nM (Xiong et al., 2008) or 3.7 µM (Oz et al., 2002). There is evidence, at least for anandamide, CP55940, and R-$(-)$-WIN55212, that this antagonism is noncompetitive in nature and, indeed, that at least some of these cannabinoids may be targeting an allosteric site on the 5-HT$_{3}$ receptor (Fan, 1995; Barann et al., 2002; Oz et al., 2002; Xiong et al., 2008).

2. Nicotinic Acetylcholine Receptors. An allosteric mechanism may also underlie the antagonism of nicotinic acetylcholine receptors that is reportedly induced by anandamide, 2-AG, R-$(-)$-methanandamide, and CP55940 ($IC_{50} = 230, 168, 183,$ and 3400 nM, respectively), although not by $\Delta^{9}$-THC or R-$(-)$-WIN55212 (Oz et al., 2003, 2004a, 2005). Evidence that anandamide can antagonize nicotinic acetylcholine receptors with significant potency has also been obtained by Spivak et al. (2007) ($IC_{50} = 300$ nM) and Butt et al. (2008) ($IC_{50} = 900$ nM). Anandamide behaved as a noncompetitive antagonist in the second of these investigations, in which further evidence that $\Delta^{9}$-THC (30 µM) is not a nicotinic acetylcholine receptor antagonist was also obtained. Arachidonic acid, a metabolite of anandamide, has also been found to antagonize nicotinic acetylcholine receptors, although the ability of anandamide to inhibit this ligand-gated ion channel does not seem to depend on its conversion to this unsaturated fatty acid (Oz et al., 2003, 2004a).

3. Glycine Receptors. At least some cannabinoid receptor agonists have been found to modulate glycine-induced activation of subunits of glycine receptors with significant potency in a positive or negative manner. Thus, for example, results obtained from experiments with transfected cells (Hejazi et al., 2006; Yang et al., 2008) suggest the following:

- Activation of human a1 subunits is enhanced by anandamide ($IC_{50} = 38$ or 319 nM), $\Delta^{9}$-THC ($IC_{50} = 86$ nM), and HU-210 ($IC_{50} = 270$ nM) but weakly inhibited by HU-308 and unaffected by R-$(-)$-WIN55212 at 30 µM.
- Activation of neither human a2 nor rat a3 subunits is affected by anandamide at up to 30 µM, whereas activation of both is inhibited by HU-210 ($IC_{50} = 90$ and 50 nM, respectively), R-$(-)$-WIN55212 ($IC_{50} = 220$ and 86 nM, respectively), and HU-308 ($IC_{50} = 1130$ and 97 nM, respectively).
- Activation of human a1b1 dimers is enhanced by anandamide and $\Delta^{9}$-THC ($IC_{50} = 318$ and 73 nM, respectively).
- Activation of human a1b2 subunits is enhanced by anandamide ($IC_{50} = 75$ nM) and HU-210 (30 µM) but unaffected by R-$(-)$-WIN55212 and inhibited by HU-308 at 30 µM.

$\Delta^{9}$-THC ($IC_{50} = 115$ nM) and anandamide ($IC_{50} = 230$ nM) have also been found to enhance the activation of native glycine receptors in rat isolated ventral tegmental area neurons (Hejazi et al., 2006). There is evidence too, from experiments with rat isolated hippocampal pyramidal neurons, that at 0.2 to 2 µM, anandamide and 2-AG can antagonize glycine receptor activation, and that this effect of anandamide is not TRPV1 channel-mediated (Lozovaya et al., 2005).

4. Other Ligand-Gated Ion Channels. Evidence has also been obtained that anandamide ($\geq 100$ nM) and R-$(-)$-methanandamide (1 µM) but not $\Delta^{9}$-THC (<10 µM) can enhance NMDA-induced activation of NMDA

---

**TABLE 5**

*Effects of cannabinoid CB$_{1}$ and/or CB$_{2}$ receptor agonists on ligand-gated ion channels*

See Section III.D for references and further details.

<table>
<thead>
<tr>
<th>Gated Channel and Effect</th>
<th>Endocannabinoid(s)?</th>
<th>Effective Concentration Range</th>
<th>Nonendogenous Cannabinoid(s)?</th>
<th>Effective Concentration Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhancement of activation</td>
<td>Glycine (native)</td>
<td>Yes</td>
<td>Nanomolar</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Glycine $\alpha_{1}$$\beta$</td>
<td>Yes</td>
<td>Nanomolar</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Glycine $\alpha_{1}$$\beta$</td>
<td>Yes</td>
<td>Nanomolar</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>NMDA</td>
<td>Yes$^{a}$</td>
<td>Nanomolar or micromolar</td>
<td>Yes$^{b}$</td>
</tr>
<tr>
<td>Inhibition of activation</td>
<td>5-HT$_{3}$</td>
<td>Yes$^{a}$</td>
<td>Nanomolar</td>
<td>Yes$^{b}$</td>
</tr>
<tr>
<td></td>
<td>Acetylcholine (nicotinic)</td>
<td>Yes$^{a}$</td>
<td>Nanomolar or micromolar</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>Glycine (native)</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Glycine $\alpha_{1}$$\alpha_{2}$</td>
<td>No</td>
<td>Micromolar</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Glycine $\alpha_{2}$$\alpha_{3}$</td>
<td>No</td>
<td>Micromolar</td>
<td>Yes</td>
</tr>
<tr>
<td>Radioligand binding (↓)</td>
<td>Benzodiazepine</td>
<td>No</td>
<td>Micromolar</td>
<td>Yes</td>
</tr>
</tbody>
</table>

$^{a}$ Also R-$(-)$-methanandamide.

$^{b}$ Only R-$(-)$-methanandamide.

$^{c}$ May target an allosteric site on this receptor.
receptors (Hampson et al., 1998). In contrast, anandamide (1–100 μM) has been found not to affect binding of [3H]muscimol to GABA_A receptors in bovine cerebral cortical synaptic membranes or, indeed, binding of the benzodiazepine [3H]flunitrazepam to these membranes (Kimura et al., 1998). Binding of [3H]flunitrazepam to synaptic membranes, however, has been found to be decreased by 11-hydroxy-A^delta^-THC at 10 μM (Yamamoto et al., 1992).

5. Conclusions. Some established endogenous and nonendogenous CB_1/CB_2 receptor agonists seem to block 5-HT_3 and nicotinic acetylcholine receptors or enhance the activation of glycine and NMDA receptors (Table 5), the relative potencies displayed by these cannabinoids as blockers or enhancers of ligand-gated ion channel activation differing from those they display as CB_1 or CB_2 receptor agonists. One CB_1 receptor antagonist/inverse agonist, LY320135, has also been found to block 5-HT_3 receptors. Many of these effects on ligand-gated ion channel activation are induced by cannabinoid concentrations in the low to mid-nanomolar range and hence with significant potency. Even so, no convincing case can be made for reclassifying glycine, NMDA, 5-HT_3, or nicotinic acetylcholine receptors as a novel cannabinoid receptor because 1) there is no evidence that glycine or NMDA receptors can be directly activated by any cannabinoid and 2) 5-HT_3 and nicotinic acetylcholine receptors are blocked rather than activated by cannabinoids; this blockade seems to be non-competitive/allosteric in nature. There is also some evidence that benzodiazepine receptors do not behave as cannabinoid receptors. Thus, there have been reports that benzodiazepine receptors are not targeted by anandamide and that although these receptors can be targeted by 11-hydroxy-A^delta^-THC, this occurs at the rather high ligand concentration of 10 μM.

E. TRPV1 and other Transient Receptor Potential Channels

1. Transient Receptor Potential Channels: A Brief Introduction. The transient receptor potential (TRP) superfamily of cation channels includes six subfamilies: “canonical,” “vaniloid” (TRPV), “melastatin” (TRPM) “polycystin,” “muco- lipin,” and “ankyrin” (TRPA). TRP channels are six-transmembrane (TM) domain integral membrane proteins with cytosolic C- and N-terminal domains and a nonselective cation-permeable pore region between TM5 and 6 (Owsianik et al., 2006). The various subfamilies differ particularly in the number of ankyrin repeats present in the N termini, which is null in TRPM and very high in TRPA channels. More than 50 members of the TRP family have been characterized in yeast, worms, insects, and fish and 28 in mammals so far (Nilius and Voets, 2005). They are involved in the transduction of a remarkable range of stimuli, including temperature, mechanical and osmotic stimuli, electrical charge, light, olfactory and taste stimuli, hypotonic cell swelling, and effects of xenobiotic substances and endogenous lipids (Venkatachalam and Montell, 2007).

It is noteworthy that mutations in different TRPs have been linked to human diseases, and their expression in tissues affected by pathological conditions is often increased (Nilius et al., 2007). To date, five types of TRP channels belonging to three subfamilies have been suggested to interact with phytoendocannabinoids, synthetic CB_1 and CB_2 receptor ligands, or endocannabinoids: TRPV1, TRPV2, TRPV4, TRPM8, and TRPA1. Data on these interactions are increasing and, importantly, have prompted two different research groups to propose that at least some TRP channels could be “ionotropic cannabinoid receptors” (Di Marzo et al., 2002; Akopian et al., 2009).

2. TRPV1 Channels. TRPV1 (initially known as VR1) was the first TRP channel to be cloned as a receptor for capsaicin, the natural product responsible for the pungency of hot chilli peppers (Caterina et al., 1997). It is also activated by noxious stimuli, such as heat (>43°C), protons (pH <6.9), and various other natural toxins. Consistent with the hypothesis that it is involved in pain, nociception, and temperature sensing (Caterina et al., 2000; Davis et al., 2000), TRPV1 is predominantly expressed in sensory neurons of unmyelinated axons (C fibers) and thin myelinated axons (Aδ fibers) of dorsal root and trigeminal ganglia (Holzer, 1988; Caterina et al., 1997; Tominaga et al., 1998), where it can become up-regulated during nerve injury-induced thermal hyperalgesia (Rashid et al., 2003b) and diabetic neuropathy (Rashid et al., 2003a). Evidence has accumulated for the presence of TRPV1 not only in sensory neurons but also in brain neurons and in non-neuronal cells, including epithelial, endothelial, glial, smooth muscle, mast and dendritic cells, lymphocytes, keratinocytes, osteoclasts, hepatocytes, myotubes, fibroblasts, and pancreatic β-cells (for review, see Starowicz et al., 2007). It is noteworthy that TRPV1 colocalizes with CB_1 receptors in sensory (e.g., dorsal root ganglia and spinal cord) (Alhuwalia et al., 2003a; Price et al., 2004) and brain (Cristino et al., 2006) neurons and with CB_2 receptors in sensory neurons (Anand et al., 2008) and osteoclasts (Rossi et al., 2009). This colocalization makes possible several types of intracellular cross-talk (for review, see Di Marzo and Cristino, 2008) and might have important functional consequences for those endogenous and synthetic ligands that activate both cannabinoid and TRPV1 receptors (Hermann et al., 2003; Fioravanti et al., 2008).

In fact, it is now well established from experimental work described in more than 300 articles that endocannabinoids, such as anandamide and N-arachidonoyl dopamine but not 2-AG, noladin ether, or virodhamine, bind to both human and rat TRPV1, upon which they act as full agonists (Zygmunt et al., 1999; for review, see Starowicz et al., 2007; Tóth et al., 2009). Although the affinity of these compounds in binding assays with the human recombinant channel is similar to, or only slightly lower than, that of capsaicin (Ross et al., 2001b; Di Marzo et al., 2002), their relative intrinsic activity and particularly their potency (Table 6) depends on the type of TRPV1 functional assay in which these pharmacological properties are assessed (i.e., enhancement of...
<table>
<thead>
<tr>
<th>Compound</th>
<th>Calcium Assay or Mesenteric Artery Tension</th>
<th>Currents by Patch Clamp</th>
<th>TRPV1</th>
<th>TRPV2</th>
<th>TRPMS</th>
<th>TRPA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anandamide</td>
<td>EC50 = 1.15 μM; EC250 = 0.63 μM; EC1000 = 0.16 μM (rat TRPV1)</td>
<td>EC50 = 4.9 μM; EC250 = 2.5 μM</td>
<td>N.E. at 100 μM</td>
<td>N.E. at 100 μM</td>
<td>IC50 = 0.15 μM (HEK293 cells) or 10 μM (DRG neurons) (vs. icilin); IC50 = 3.1 μM (vs. menthol in HEK293 cells)*</td>
<td>EC50 = 4.9 μM</td>
</tr>
<tr>
<td>2-AG</td>
<td>N.E. at 10 μM; EC50 = 8.4 μM</td>
<td>EC50 = 1.6 μM (DRG); 794 nM (TG)</td>
<td>N.T.</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.T.</td>
</tr>
<tr>
<td>NADA</td>
<td>EC50 = 26 nM</td>
<td></td>
<td>N.T.</td>
<td>N.E.</td>
<td>N.E.</td>
<td>N.T.</td>
</tr>
<tr>
<td>OEA</td>
<td>EC50 = 3.7 μM; EC250 = 0.4 μM</td>
<td>EC50 = 6.3 μM</td>
<td>N.T.</td>
<td>EC50 = 15.5 μM</td>
<td>N.T.</td>
<td>N.T.</td>
</tr>
<tr>
<td>Δ⁴-THC</td>
<td>N.E. at 100 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td>IC50 = 0.16 μM (vs. icilin); IC50 = 0.15 μM (vs. menthol)*</td>
<td></td>
</tr>
<tr>
<td>HU-210</td>
<td>EC50 = 1.2 μM but very low maximal effect; no effect at 100 μM</td>
<td></td>
<td>N.T.</td>
<td>Slight agonism at 100 μM</td>
<td>N.T.</td>
<td></td>
</tr>
<tr>
<td>CP55940</td>
<td>N.E. at 100 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R(+-)-WIN555212</td>
<td>Slight effect at 100 μM</td>
<td></td>
<td>N.E.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rimonabant</td>
<td>Antagonist 1–5 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JWH-015</td>
<td>EC50 = 41.2 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>EC50 = 3.5 μM (human)<em>; very little effect (rat)</em></td>
<td>EC50 = 3.7 μM</td>
<td>N.E. at 100 μM</td>
<td></td>
<td>IC50 = 80 nM (vs. icilin); IC50 = 0.14 μM (vs. menthol)*</td>
<td></td>
</tr>
<tr>
<td>Cannabinol</td>
<td>N.E. at 100 μM</td>
<td>EC50 = 77.7 μM</td>
<td>N.T.</td>
<td></td>
<td>IC50 = 0.21 μM (vs. icilin)*</td>
<td></td>
</tr>
<tr>
<td>Cannabichrome</td>
<td>EC50 &gt; 50 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabigerol</td>
<td>EC50 = 11.5 μM</td>
<td></td>
<td>N.T.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.E., no effect; N.T., not tested; NADA, N-arachidonoyl dopamine; OEA, oleoyl ethanolamide; TG, trigeminal ganglia.

*a Smart et al., 2000.
*b De Petrocellis et al., 2000.
*c Movahed et al., 2005.
*d Zymunt et al., 1999.
*e Roberts et al., 2002.
*f Qin et al., 2008.
*g De Petrocellis et al., 2007.
*h De Petrocellis et al., 2008.
*i De Petrocellis and Di Marzo, 2009.
+j McDonald et al., 2008.
+k L. De Petrocellis and V. Di Marzo, unpublished observations.
+l Appendino et al., 2009.
+m Jordi et al., 2004.
+n De Petrocellis et al., 2001.
+o Bisogno et al., 2001.
p Ligresti et al., 2006.
intracellular Ca\(^{2+}\) levels, induction of cation currents in neurons, or release of allogenic/vasodilatory peptides from sensory nervous tissue preparations) and on the experimental conditions used to carry out these assays. Furthermore, TRPV1 gating by its ligands can be markedly altered by several regulatory events and signals, including post-translational modifications (such as phosphorylation by several protein kinases), allosteric modulation by temperature, acid, membrane potential, membrane phospholipids (phosphatidylinositol bisphosphate in particular), metabotropic (including cannabinoid) receptor activation, neurotrophins, etc., all of which can be modulated by inflammatory and other pathological conditions. As a result, apparent anandamide-induced activation of TRPV1 has often been found to increase or decrease under such conditions. It has been proposed, for example, that endogenously released anandamide has higher efficacy and potency (Abu-Luwaileh et al., 2003b). Although anandamide may be less potent as a TRPV1 agonist than as a CB\(_1\) receptor agonist, elevation of its endogenous levels with fatty acid amide hydrolase (FAAH) inhibitors [e.g., cyclohexylcarbamate acid 3'-carbamoyl-biphenyl-3-yl ester (URB597)] can lead to effects that are mediated by TRPV1 (Maione et al., 2006; Morgese et al., 2007; Rubin et al., 2008). This, together with data indicating that exogenous anandamide can exert effects at TRPV1 in a way sensitive to inhibitors of anandamide cellular uptake in HEK293 cells (De Petrocellis et al., 2001), trigeminal neurons (Price et al., 2005b), and, ex vivo, in mesenteric arteries (Andersson et al., 2002) represents strong indirect evidence that both endogenous and exogenous anandamide reaches its intracellular binding site on this molecular target.

It is noteworthy that anandamide and N-arachidonoyl dopamine seem to interact with TRPV1 at the same intracellular binding site as capsaicin. Jordt and Julius (2002) observed that the TM3/4 region of the mammalian TRPV1 receptor is responsible for its sensitivity to capsaicin and anandamide, whereas the avian receptor, which is activated only by heat or protons, lacks part of this region. The binding site is located on the inner face of the plasma membrane, thus opening up the possibility that when anandamide is biosynthesized by cells that express TRPV1, it will activate this receptor before being released, thereby regulating Ca\(^{2+}\) homeostasis as an intracellular messenger (van der Stelt et al., 2005). A crucial role for Tyr511 and Ser512, located at the transition between the second intracellular loop and TM3, has been demonstrated, and other critical residues seem to be in the TM4 segment (Jordt and Julius, 2002; Johnson et al., 2006). Tyr511 engages in a hydrophobic interaction with the hydrophobic tails of capsaicin, anandamide, and N-arachidonoyl dopamine, whereas the side-chain hydroxyl group of Thr550, as well as the aromatic region of Trp549, both present in the TM4 domain, might interact with the vanillyl, catecholamine, or ethanolamine moiety of TRPV1 ligands.

Synthetic CB\(_1\) and CB\(_2\) receptor ligands, such as HU-210, JWH-015, and rimonabant, have also been reported to interact with TRPV1, although usually with lower relative intrinsic activity and potency than anandamide, whereas N-arachidonoyl dopamine displays markedly greater potency than anandamide as a TRPV1 agonist (Table 6) (De Petrocellis et al., 2001; Qin et al., 2008). In contrast, phytocannabinoids that do not activate CB\(_1\) receptors, such as cannabidiol and cannabinerol (section II.C.5), were shown to act as full agonists at TRPV1 receptors (Bisogno et al., 2001; Ligresti et al., 2006). Cannabidiol, in particular, exhibits almost the same \(K_i\) as capsaicin at the human TRPV1 receptor (Bisogno et al., 2001), but seems to be significantly less potent at rat TRPV1 (Qin et al., 2008). It is noteworthy that anandamide and N-arachidonoyldopamine congeners with little or no activity at CB\(_1\)/CB\(_2\) receptors, such as oleoyl ethanolamide, linoleoyl ethanolamide, and N-oleoyl dopamine (section II.C.5), are also potent TRPV1 agonists (Movahed et al., 2005).

3. Other TRPV Channels. Apart from TRPV1, five other TRPV channels, all insensitive to capsaicin, have been identified and cloned to date. TRPV2, -3, and -4 are involved in high-temperature sensing and nociception, whereas TRPV5 and -6 intervene in Ca\(^{2+}\) reabsorption (for review, see Vennekens et al., 2008). TRPV2 was previously known as growth factor-regulated Ca\(^{2+}\) channel or vanilloid receptor-like 1 and is activated by higher temperatures than TRPV1, but not by protons (Qin et al., 2008). Strong evidence (albeit obtained so far in only one laboratory) exists for the interaction of cannabidiol, \(\Delta^8\)-THC, cannabinol, and, to a smaller extent, 11-hydroxy-\(\Delta^8\)-THC, nabilone, CP55940, and HU-210, with TRPV2. These effects were observed by measuring elevation of intracellular Ca\(^{2+}\) in HEK293 cells transfected with rat recombinant TRPV2 cDNA. Apart from cannabidiol, these compounds exhibited EC\(_{50}\) values much higher, or \(E_{\text{max}}\) values much lower, than those observed in functional assays that measure cannabinoid receptor-mediated responses (Table 6). It is noteworthy that cannabidiol has also been found to evoke TRPV2-mediated cation currents and release of calcitonin gene-related peptide in cultured dorsal root ganglion (DRG) neurons (Qin et al., 2008). Because TRPV2, like TRPV1, is immediately desensitized by its agonists, these findings might explain some of the anti-inflammatory and/or analgesic properties of cannabidiol.

TRPV4 is activated by a variety of physical and chemical stimuli, including heat and decreases in osmolarity (Everaerts et al., 2010). TRPV4 was originally reported to be activated by anandamide and 2-AG, probably via the formation of cytochrome P450 metabolites of arachidonic acid, such as epoxyeicosatrienoic acids (Watanabe et al., 2003). It is noteworthy that cytochrome P450 metabolites of anandamide activate cannabinoid recep-
tors (Chen et al., 2008) but have never been tested on TRPV4.

4. Other TRP Channels: TRPM8 and TRPA1. TRPM8 and TRPA1 belong to two subfamilies different from that of the capsaicin (TRPV1) receptor but are still involved in thermosensation. Indeed, TRPM8 and TRPA1 were suggested to be activated by cold temperatures as well as by natural compounds (such as menthol in the case of TRPM8) and by various irritants ([mustard oil isothiocyanates, acrolein, etc.) in the case of TRPA1] (for review, see McMurry 2005). Recent evidence has emerged that both anandamide and N-arachidonoyl dopamine, but not 2-AG, can efficaciously antagonize the stimulatory effect of two TRPM8 agonists, menthol and the synthetic compound icilin, on intracellular Ca2+

Evidence that TRPA1 (ANKTM1) is activated by phytocannabinoid CB1/CB2 receptor agonists [i.e., Δ⁹-THC and cannabidiol (sections II.C.1 and II.C.5)], was first described in the article reporting the cloning of this channel (Jordt et al., 2004). The authors of this article showed that concentrations of these two compounds ≥10 μM were necessary to induce TRPA1-mediated effects, including endothelium- and CB1/CB2-independent vasodilation of rat mesenteric arteries. Later, Akopian et al. (2008) showed that micromolar concentrations of R-(+)-WIN55212 as well as the CB2-selective agonist AM1241 1) elicited TRPA1-mediated elevation of Ca2+ and currents in transfected CHO cells and trigeminal neurons; 2) desensitized TRPA1- and TRPV1-expressing cells to the action of capsaicin; 3) inhibited capsaicin-evoked nocifensive behavior in vivo in wild-type mice and much less so in TRPA1-null mutant mice (Akopian et al., 2008). Qin et al. (2008) recently confirmed that Δ⁹-THC and R-(+)-WIN55212 activate rat recombinant TRPA1 and also found that the cannabinoid receptor-inactive isomer of the latter compound, S-(-)-WIN55212, exerts a similar action, although at higher concentrations. Furthermore, the cannabinoid quinone 3SAR-p-benzoquinone-3-hydroxy-2-p-mentha-(1,8)-dien-3-yl-5-pentyl (HU-331) was also quite potent. Almost at the same time, De Petrocellis et al. (2008) found that in HEK293 cells transfected with rat TRPA1, Δ⁹-THC could be much more potent at eliciting TRPA1-mediated elevation of intracellular Ca2+

5. Conclusions. That some endocannabinoids, particularly anandamide, exert pharmacological effects in vivo by activating TRPV1 receptors has now been demonstrated in hundreds of investigations, including some in which supporting evidence was obtained from experiments with TRPV1-null mice. Furthermore, although Δ⁹-THC exerts only very weak effects at TRPV1, phytocannabinoids that do not activate CB1/CB2 receptors, on the one hand, and synthetic CB1/CB2 ligands, on the other hand, have been shown to interact with this protein with significant potency and/or relative intrinsic activity. Thus, a strong case can be made for classifying TRPV1 as an “ionotropic cannabinoid receptor,” although this channel is clearly targeted less selectively than cannabinoid CB1 or CB2 receptors because its activity can be directly modulated by several endogenous or xenobiotic compounds that are not CB1 or CB2 receptor ligands. The capability of endocannabinoids and cannabidiol to inhibit TRPM8 functional responses might be a consequence, in part, of their agonist activity at TRPV1, because it has been observed that most of the regulatory events and mediators that affect this latter channel in one direction often affect the TRPM8 channel in the opposite direction (De Petrocellis et al., 2007). Further studies should be carried out to investigate fully the possibility that TRPA1 mediates some of the pharmacological effects of phytocannabinoids and/or synthetic Δ⁹-THC-mimetic compounds, although the fact that this TRP channel is also extremely promiscuous in its responsiveness to physiological and synthetic ligands should be kept in mind. Finally, too little evidence exists to date to allow any conclusions to be drawn about whether or not other TRP channels (e.g., TRPV2 and TRPV4) might be putative cannabinoid receptors.

F. Other Ion Channels

1. Calcium Channels. Certain cannabinoid receptor agonists (Table 7) and antagonists have been found to antagonize T-type voltage-gated calcium channels at concentrations in the mid-nanomolar or low micromolar range. Thus, for example, evidence has been obtained (Chemin et al., 2001, 2007; Ross et al., 2008, 2009) for CB1 receptor-independent inhibition of the following:
TABLE 7

Apparent cannabinoid CB₁ receptor-independent effects of cannabinoid receptor agonists on ion channels other than TRP channels

See Section III.F for references and further discussion.

<table>
<thead>
<tr>
<th>Ion Channel and Reference</th>
<th>Endocannabinoid(s)?</th>
<th>Effective Concentration Range</th>
<th>Nonendogenous Cannabinoid Agonist(s)?</th>
<th>Effective Concentration Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current enhancement/activation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kᵥ (BK) K⁺</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
</tr>
<tr>
<td>Voltage-gated Na⁺</td>
<td>No</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca²⁺ (native)</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>T-type Ca²⁺ (CaV₃.1)</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>T-type Ca²⁺ (CaV₃.2)</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>T-type Ca²⁺ (CaV₃.3)</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>T-type Ca²⁺ (native)</td>
<td>N.D.</td>
<td>N.D.</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>N-, P-, or P/Q-type Ca²⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>TASK-1 K⁺</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
<td>Yes</td>
<td>Nanomolar or micromolar</td>
</tr>
<tr>
<td>TASK-3 K⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Voltage-gated K⁺ (Kᵥ)</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Voltage-gated Na⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Radioligand binding (Δ)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-type Ca²⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Kᵥ, Ca²⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
<tr>
<td>Voltage-gated Na⁺</td>
<td>Yes</td>
<td>Micromolar</td>
<td>Yes</td>
<td>Micromolar</td>
</tr>
</tbody>
</table>

N.D., no data.

a Anandamide but not 2-arachidonoyl glycerol.

b Only R(+) methanandamide.

c Also R(+) methanandamide.

d May target an allosteric site on this ion channel.

e Slight enhancement of sodium currents has also been detected in response to 10 nM R(+) WIN55212 (section III.G.3.).

- Cloned CaV₃.1 channels by anandamide (IC₅₀ = 4.2 μM), R(+)-methanandamide (10 μM), N-arachidonyl dopamine (IC₅₀ = 513 nM), ACEA (10 μM), and Δ⁹-THC (IC₅₀ = 1.6 μM).
- Cloned CaV₃.2 channels by anandamide (IC₅₀ = 330 nM), N-arachidonyl dopamine (IC₅₀ = 1122 nM), R(+)methanandamide (1 μM), ACEA (10 μM), Δ⁹-THC (IC₅₀ = 1.3 μM), HU-210 (10 but not 1 μM) and rimonabant (100 nM and 1 μM) but not by CP55940, R(+) WIN55212, or 2-AG at 10 μM.
- Cloned CaV₃.3 channels by anandamide (IC₅₀ = 1.1 μM) and N-arachidonyl dopamine (IC₅₀ = 355 nM), by R(+)methanandamide and ACEA at 10 μM, and by Δ⁹-THC (4.3 μM).
- Native T-type calcium channels by R(+)methanandamide and Δ⁹-THC at 1 μM and AM251 at 3 μM, but not by R(+) WIN55212 at 1 μM.

It is noteworthy that the phytocannabinoid cannabidiol has also been found to inhibit cloned CaV₃.1, CaV₃.2, and CaV₃.3 calcium channels, its reported IC₅₀ values for this inhibition being 813, 776, and 3631 nM, respectively (Ross et al., 2008). In addition, a recent article reported that the endogenous lipo-amino acids, NAGly and N-arachidonyl GABA, can potently inhibit CaV₃.1, CaV₃.2, and CaV₃.3 channels (IC₅₀ < 1.0 μM) (Barbara et al., 2009).

In addition, there is evidence that anandamide, 2-AG, and R(+)methanandamide but not Δ⁹-THC, CP55940, or R(+) WIN55212 can bind to L-type voltage-gated calcium channels, possibly in a noncompetitive/allosteric manner, their reported IC₅₀ or apparent Kᵢ values ranging from 3.2 to 40 μM (Johnson et al., 1993; Shimasue et al., 1996; Jarrahian and Hillard, 1997; Oz et al., 2000, 2004b). There have also been reports that 1) displacement of [n-methyl-³H]diltiazem from L-type calcium channels can be induced by both rimonabant (IC₅₀ = 6.1 μM) and tazarotene (IC₅₀ = 300 nM) (Fong et al., 2009); 2) that anandamide (100 nM) and rimonabant (1 μM) can inhibit potassium-evoked Ca²⁺ influx into neonatal rat cultured DRG sensory neurons (Evans et al., 2004); and 3) that anandamide at 1 μM and 2-AG and R(+)-methanandamide, but not Δ⁹-THC, CP55940, or R(+) WIN55212 at 10 μM, can inhibit depolarization-induced Ca²⁺ influx in transverse tubule membrane vesicles (Oz et al., 2000, 2004b). The data obtained in these investigations suggest that these effects of anandamide, 2-AG, and R(+)-methanandamide on calcium flux were not CB₁ receptor-mediated.

There is also evidence that at least some cannabinoids can antagonize N-, P-, and P/Q-type voltage-gated calcium channels. Thus, there have been reports that N- or P/Q-type channels can be antagonized at 10 μM by R(+)-WIN55212, S(-)-WIN55212, and anandamide, although not by 2-AG or noladin ether (Shen and Thayer, 1998; Guo and Ikeda, 2004), and that P-type channels can be antagonized by R(+)-WIN55212 (10 μM), anandamide (IC₅₀ = 1.04 μM), R(+)-methanandamide (2 μM), and 2-AG (10 μM) (Fisyunov et al., 2006). These effects on N-, P-, and P/Q-type channels seemed not to be CB₁ receptor- or TRPV1 receptor-mediated. Arachidonic acid can also target T-, P-, and L-type channels, but it is unlikely that the ability of anandamide to antagonize these channels depends on its metabolic conversion to this acid (Shimasue et al., 1996; Jarrahian and Hillard, 1997; Oz et al., 2000; Chemin et al., 2001, 2007; Fisyunov et al., 2006).

2. Potassium Channels. Results obtained in a number of investigations suggest that several types of potassium...
channel can be targeted by certain cannabinoid receptor agonists (Table 7) and antagonists in a cannabinoid CB1 receptor-independent manner at concentrations in the nanomolar or low micromolar range. These are members of the 2TM domain family of channels (K_{ATP} channels), the 4TM domain family of leak or background channels (TASK and TREK), and the 6TM domain family of voltage-gated channels (K_V and calcium-activated K_{Ca} channels).

Turning first to ATP-sensitive inward-rectifier (K_{ATP}) channels, there is evidence that anandamide is a non-competitive inhibitor of such channels (IC_{50} = 8.1 μM) and that this endocannabinoid also inhibits [³H]glibenclamide binding to K_{ATP} channels, again in a noncompetitive manner (IC_{50} = 6.3 μM). These channels can be inhibited by R-(+)-methanandamide at 10 μM but not by rimonabant or SR144528 at 1 μM (Oz et al., 2007).

Moving on to the 4TM domain family, it has been found that human or rat TASK-1 channels can be inhibited by R-(+)-methanandamide (IC_{50} = 700 nM), by anandamide at 3 and 10 μM, and by rimonabant (slight inhibition), CP55940, and R-(+)-WIN55212 but not Δ^9-THC, HU-210, or 2-AG at 10 μM (Maingret et al., 2001; Berg et al., 2004; Veale et al., 2007; Zhang et al., 2009). There have also been reports that human, rat, or mouse TASK-3 channels can be inhibited by R-(+)-methanandamide and anandamide at 1 to 10 μM (Berg et al., 2004; Veale et al., 2007) and that bovine TREK-1 channels are inhibited by anandamide (IC_{50} = 5.1 μM) (Liu et al., 2007).

As to K_V channels, there is evidence for the following:

- K_V1.2 channels are inhibited by anandamide (IC_{50} = 2.7 μM), arachidonic acid (IC_{50} = 6.6 μM), and Δ^9-THC (IC_{50} = 2.4 μM) (Poling et al., 1996).
- Human cardiac K_V1.5 channels are inhibited by anandamide (IC_{50} = 0.9 μM), 2-AG (IC_{50} = 2.5 μM), and, with a similar potency, by both R-(+)-methanandamide and arachidonic acid (Barana et al., 2010).
- Human K_V1.5 channels expressed on HEK293 cells are also blocked by anandamide, which displays significantly greater potency intracellularly (IC_{50} = 213 nM) than extracellularly (IC_{50} = 2.1 μM) (Moreno-Galindo et al., 2010).
- K_V3.1 channels are inhibited by anandamide (0.1–3 μM) and arachidonic acid (3 μM) (Oliver et al., 2004) and cardiac K_V4.3 channels are inhibited by anandamide (IC_{50} = 400 nM), R-(+)-methanandamide (IC_{50} = 600 nM), and 2-AG (IC_{50} = 300 nM) (Amorós et al., 2010).

In addition, there has been a report that K_V channels can be inhibited not only by anandamide (IC_{50} = 600 nM) and R-(+)-methanandamide (10 μM) but also by rimonabant (10 μM) and R-(+)-WIN55212 (20 μM), although not by arachidonic acid (Van den Bossche and Vanheel, 2000). It has been found too that both rimonabant (IC_{50} = 2.5 μM) and taranabant (IC_{50} = 2.3 μM) can induce radiolabeled ligand displacement from rapid delayed rectifier K_V channels (Fong et al., 2009). Evidence has also recently been obtained that anandamide (1 μM) can strongly inhibit K_V channel-mediated delayed rectifier outward potassium current (Vignali et al., 2009). A similar degree of inhibition was induced by R-(+)-methanandamide (1 μM). However, both R-(+)-WIN55212 and 2-AG induced less inhibition at 1 μM than anandamide.

Finally, there is evidence that anandamide (EC_{50} = 631 nM or 4.8 μM) and R-(+)-methanandamide (EC_{50} = 7.9 μM) but not 2-AG (up to 10 μM) can increase the activity of K_{Ca} (BK) channels (White et al., 2001; Godlewski et al., 2009). Results obtained in experiments with rat isolated coronary arteries also suggest that such activation can be produced by both anandamide and R-(+)-methanandamide at concentrations of 0.3 to 3 μM, although not by JWH-133 at 1 μM (Sade et al., 2006).

3. Sodium Channels. There is evidence that voltage-gated sodium channels can be targeted by some cannabinoid receptor agonists at concentrations in the nanomolar or micromolar range (Table 7). Thus, for example, R-(+)-WIN55212 has been found by Fu et al. (2008) to induce a slight enhancement (11.5%) of voltage-gated sodium currents in rat cultured trigeminal ganglion neurons at 10 nM but to inhibit these currents at higher concentrations (IC_{50} = 17.8 μM). In an earlier investigation, Nicholson et al. (2003) also found that R-(+)-WIN55212 can inhibit voltage-gated sodium channels. More specifically, they obtained evidence that this aminoaalkylindolone can act in a CB1 receptor-independent manner to inhibit 1) depolarization of mouse brain synaptoneurosomes induced by the sodium channel-selective activator veratridine (IC_{50} = 21.1 μM); 2) veratridine-dependent release of L-glutamic acid (IC_{50} = 12.2 μM) and γ-aminobutyric acid (IC_{50} = 14.4 μM) from mouse purified whole-brain synaptosomes; and 3) the binding of the sodium channel site 2-selective ligand [³H]batrachotoxinin A 20-α-benzoate, to mouse brain synaptoneurosomal voltage-gated sodium channels (IC_{50} = 19.5 μM). Anandamide displayed similar inhibitory activity in these four bioassays (IC_{50} = 21.8, 5.1, 16.5, and 23.4 μM, respectively) (Nicholson et al., 2003) as did AM251 (IC_{50} = 8.9, 8.5, 9.2, and 11.2 μM, respectively) (Liao et al., 2004). CP55940, N-arachidonoyl dopamine, noladin ether, and 2-AG have also been found to displace [³H]batrachotoxinin A 20-α-benzoate from mouse brain synaptoneurosomal voltage-gated sodium channels (IC_{50} = 22.3, 20.7, 51.2, and 90.4 μM, respectively) (Duan et al., 2008a,b). The mechanism underlying the inhibition of binding induced in this assay by these four compounds, and by AM251 and anandamide but not by R-(+)-WIN55212, could well be allosteric in nature (Nicholson et al., 2003; Liao et al., 2004; Duan et al., 2008a,b). It has been found too by Duan et al. (2008a) that the ability of R-(+)-WIN55212 and anandamide to inhibit veratridine-dependent depolarization of mouse synaptoneurosomes (Nicholson et al., 2003) extends to CP55940 (IC_{50} = 3.2 μM). This inhibition was produced by CP55940 in a noncompetitive manner. There have also been reports that voltage-gated sodium channels can be inhibited by anandamide in rat DRG sensory neurons (apparent K_{d} = 5.4 and 38.4 μM for tetrodotoxin-sensitive and tetrodotoxin-resistant so-
dium currents, respectively) (Kim et al., 2005) and by \(R^-(+)-\)
WIN55212 (10 \(\mu\)M) and noladin ether (50 \(\mu\)M) in frog para-
thyroid cells (Okada et al., 2005).

4. Conclusions. Several established endogenous and nonendogenous CB1/CB2 receptor agonists and some CB1 receptor antagonists can induce CB1 receptor-independent blockade of certain types of calcium, potassium, and sodium channels (Table 7), sometimes in an apparently noncompet-
titive/allosteric manner. Such blockade is induced by these agonists and antagonists at micromolar or nanomolar con-
centration. There is also evidence that anandamide and \(R^-(+)-\)methanandamide can activate \(K_c\) (BK) channels and that a subinhibitory concentration of \(R^-(+)-\)WIN55212 (10 nM) can enhance voltage-gated sodium currents. Given the relatively high (nanomolar) potency with which \(C_9\) 3,2, K\(_a\) 1.5, and \(K_{cs}\) (BK) channels can apparently be targeted by anandamide, further research directed at seeking out CB1 receptor-independent physiological and/or pathological roles of these ion channels in the endocannabinoid system is clearly warranted.

G. Peroxisome Proliferator-Activated Receptors

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that constitute part of the nuclear receptor family (Michalik et al., 2006). Activated PPARs form functional units as heterodimers with retinoic X receptors. Classical agonists at PPARs are fatty acids and their derivatives, ranging from oleic acid and arachidonic acid to leukotriene B\(_4\) and 15-deoxy-\(\Delta_\text{12,14}\)-prostaglandin J\(_2\). It is a widespread view that PPARs are not activated by a single endoge-
nous ligand but are generalized lipid sensors, monitoring local changes in metabolism. There are three PPAR isoforms, PPAR\(_\alpha\), PPAR\(_\beta\), and PPAR\(_\gamma\). PPAR\(_\alpha\) is the target of the clinically employed antihyperlipidemic fibrates, including gemfibrozil and fenofibrate. PPAR\(_\gamma\) is a therapeutic target in type 2 diabetes. Its ligands include pioglitazone, rosiglitazone, and troglitazone, which are known collectively as thiazolidinediones. PPAR\(_\beta\) is also known as PPAR\(_\beta\) on the basis of differential naming of species orthologs and has yet to be targeted effectively in the clinic. All three isoforms are expressed in liver to some degree, although PPAR\(_\alpha\) predominates in skeletal muscle and PPAR\(_\gamma\) in adipose tissue. Because they are nuclear receptors, signal trans-
duction at PPARs is primarily directed through alterations in gene transcription. A number of PPAR target genes have been identified, many of which are associated with lipid turnover, such as long-chain fatty acyl-CoA dehydrogenase and lipoprotein lipase; these are often used as markers of PPAR activation both in vitro and in vivo.

1. Direct Evidence for Peroxisome Proliferator-Acti-


TABLE 8

Potency of cannabinoids and endocannabinoid-like molecules at peroxisome proliferator-activated receptors (EC\(_{50}\) or IC\(_{50}\) values or effective concentrations)

<table>
<thead>
<tr>
<th>Cannabinoid or Related Molecule</th>
<th>PPAR(_\alpha)</th>
<th>PPAR(_\beta)</th>
<th>PPAR(_\gamma)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoyl ethanolamide</td>
<td>3(^i)</td>
<td>&gt;30(^i)</td>
<td>&gt;30; 1(^i)</td>
</tr>
<tr>
<td>Stearoyl ethanolamide</td>
<td>&gt;30(^j)</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>Oleoyl ethanolamide</td>
<td>0.12; 0.12(^k)</td>
<td>1(^l)</td>
<td>&gt;10(^l)</td>
</tr>
<tr>
<td>Anandamide</td>
<td>&gt;10; 10 to 30(^m)</td>
<td>N.D.</td>
<td>8(^n); 10(^o)</td>
</tr>
<tr>
<td>2-AG</td>
<td>N.D.</td>
<td>&gt;1(^p)</td>
<td>10; &gt;30; 10(^p)</td>
</tr>
<tr>
<td>Noladin ether</td>
<td>10 to 30(^q)</td>
<td>N.D.</td>
<td>&gt;30(^q)</td>
</tr>
<tr>
<td>Virodhamine</td>
<td>10 to 30(^r)</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>(R^-(+)-)WIN55212</td>
<td>20(^s)</td>
<td>N.D.</td>
<td>N.D.</td>
</tr>
<tr>
<td>(\Delta^2)-THC</td>
<td>&gt;100(^t)</td>
<td>N.D.</td>
<td>&gt;0.3(^t)</td>
</tr>
<tr>
<td>Cannabidiol</td>
<td>N.D.</td>
<td>5(^u)</td>
<td>5(^u)</td>
</tr>
<tr>
<td>Ajulemic acid</td>
<td>&gt;50(^v)</td>
<td>&gt;50(^v)</td>
<td>0.6; 13(^v)</td>
</tr>
<tr>
<td>Rimonabant</td>
<td>Activation(^w)</td>
<td>N.D.</td>
<td>10(^w)</td>
</tr>
<tr>
<td>AM251</td>
<td>Activation(^w)</td>
<td>N.D.</td>
<td>10(^w)</td>
</tr>
</tbody>
</table>

N.D., no data.

\(^a\) EC\(_{50}\) reporter gene assay in HeLa cells expressing recombinant receptors (Lo Verme et al., 2005a).

\(^b\) EC\(_{50}\) reporter gene assay in COS cells expressing recombinant receptors (Bouaboula et al., 2005).

\(^c\) EC\(_{50}\) reporter gene assay in HeLa cells expressing recombinant receptors (Bu et al., 2003).

\(^d\) EC\(_{50}\) reporter gene assay in MCF7 cells expressing recombinant receptors (Alvarado et al., 2008).

\(^e\) IC\(_{50}\) competition for fluorescent ligand occupancy of ligand binding domain (Sun et al., 2007a).

\(^f\) IC\(_{50}\) competition for fluorescent ligand occupancy of ligand binding domain (Bouaboula et al., 2005).

\(^g\) EC\(_{50}\) reporter gene assay in human umbilical vein endothelial cells in the presence of a COX-2 inhibitor (Ghosh et al., 2007).

\(^h\) EC\(_{50}\) reporter gene assay in 3T3-L1 cells expressing recombinant receptors (Rockwell et al., 2006).

\(^i\) EC\(_{50}\) reporter gene assay in HEK293 cells expressing recombinant receptors (O’Sullivan et al., 2005).

\(^j\) IC\(_{50}\) competition for fluorescent ligand occupancy of ligand binding domain (O’Sullivan et al., 2005b).

\(^k\) EC\(_{50}\) reporter gene assay in HEK293 cells expressing recombinant receptors (O’Sullivan et al., 2006; Sun et al., 2007b).

\(^l\) Effective concentration in reporter gene assay in HEK293 cells expressing recombinant receptors; ligand concentration(s) for PPAR\(_\alpha\) activation not published (O’Sullivan et al., 2006; Sun et al., 2007b).

archetypal endocannabinoids anandamide and 2-AG as well as the phytocannabinoids \(\Delta^2\)-THC and cannabidiol and the synthetic cannabinoids \(R^-(+)-\)WIN55212 and ajulemic acid (Table 8). The potency of the majority of these agents is approximatel-

\(\Delta^2\)-THC (O’Sullivan et al., 2005) and \(R^-(+)-\)WIN55212 (Giuliano et al., 2009) at 100 nM. There are also reports that rimonabant and AM251 can activate both PPAR\(_\gamma\) (at 10 \(\mu\)M) and PPAR\(_\alpha\) (O’Sullivan et al., 2006; Sun et al., 2007b). However, it remains unclear whether this represents a direct or indirect phenomenon associated with high ligand concentrations. Two fatty acid eth-

anolamides (oleoyl ethanolamide and palmitoyl ethanol-

amide), which are essentially inactive at cannabinoid CB\(_1\) and CB\(_2\) receptors, are agonists with reasonable potency at PPAR\(_\alpha\) (Table 8). This receptor seems to display some preference for the medium-chain mono- or diunsat-

urated fatty acid ethanolamides, such as oleoyl eth-

anolamide and linoleoyl ethanolamide, compared with the long-chain polyunsaturated fatty acid ethanol-

amides, such as anandamide, N-eicosapentaenyleth-

Downloaded from pharmrev.aspetjournals.org on July 25, 2023
anolamine and N-docosohexaenoyl ethanolamine (Artmann et al., 2008).

Oxidative metabolism of endocannabinoids generates agents that are also active at PPARs. Thus, 15-
lipoxigenase metabolism of 2-AG leads to the production of 15(S)-hydroxyeicosatetraenoic acid-glycerol ester (Kozak et al., 2002). This agent was identified as a preferential agonist at PPARα in a reporter gene assay using NIH 3T3 cells as hosts, with an EC50 value of ~3 µM, but was inactive up to 10 µM at PPARβ or PPARγ. It is noteworthy that the arachidonic acid metabolite 15(S)-hydroxyeicosatetraenoic acid at 10 µM is a preferential PPARγ agonist (Kozak et al., 2002). 2-(14,15-Epoyxeycosatrienoyl)glycerol (a product of 2-AG metabolism by epoxigenase) but not 2-AG itself also appeared to be a PPARα agonist (Fang et al., 2006). However, mass spectrometry analysis suggested that the active entity was 14,15-dihydroxyeicosatrienoic acid, produced through sequential hydrolysis of the glyceryl ester and epoxide bonds. One of the problems this study highlights is that the extended periods necessary for identification of agonist action at PPARs (4 h or more) increases the potential for conversion of the added agent into an entity with altered activity at the receptor.

2. Indirect Evidence for Cannabinoid Activation of Peroxisome Proliferator-Activated Receptors. Indirect means of identifying an action of cannabinoid-related molecules at PPARs include 1) the use of reporter genes in model cells where PPARs are either endogenously expressed or overexpressed and 2) the use of pharmacological or genetic inhibition of PPARs.

3. Reporter Gene Assays and Metabolism of Endocannabinoids. COX-2-mediated metabolism of 2-AG, noladin ether, and anandamide led to greater activation of PPARβ compared with PPARγ, with no discernible PPARα activation, in human umbilical vein endothelial cells transfected with peroxisome proliferator-activated response element coupled to a reporter gene (Ghosh et al., 2007). COX-2 inhibition alone did not alter PPAR activation, suggesting that conversion of endogenous COX-2 substrates was not sufficient to activate PPARs. 2-AG itself, in the presence of a COX-2 inhibitor, was ineffective, indicating that COX-2 metabolism was an obligatory step in the production of a PPAR ligand. siRNA knockdown of prostacyclin synthase (CYP8A1) inhibited PPAR activation, demonstrating that prostaglandin 1(S)-glyceride was probably the endogenous ligand, although attempts to identify endogenous levels of this agent using mass spectrometry were unsuccessful (Ghosh et al., 2007).

4. Antagonism. In mouse primary splenocytes in vitro, anandamide evoked a concentration-dependent inhibition of interleukin-2 secretion that was not blocked by rimonabant or SR144528 but was inhibited by 2-chloro-5-nitro-N-4-pyrindinyl-benzamide (T0070907), indicating a role for PPARγ in these effects (Rockwell and Kaminski, 2004). Sequential metabolism in HeLa human cervical carcinoma cells by COX-2 and lipocalin type-prostaglandin D synthase led to activation of PPARγ by 1R(−)-methanandamide, as evidenced by siRNA and 2-chloro-5-nitro-N-phenylbenzamide (GW9662) inhibition (Eichele et al., 2009). In vitro, the PPARγ antagonist GW9662 was able to block relaxations evoked by cannabidiol (OSullivan et al., 2009b), Δ9-THC (OSullivan et al., 2005), N- arachidonoyl dopamine and anandamide (OSullivan et al., 2009a) in rat isolated aorta. R(+)-WIN55212-evoked apoptosis of HepG2 human hepatoma cells was inhibited by GW9662 (Giuliano et al., 2009). Prolonged exposure of these cells to R(+)-WIN55212 also induced increased expression of PPARγ, a response associated with PPARγ activation. Likewise, HU-210 exposure over several days increased PPARγ expression in 3T3-P442A mouse preadipocyte cells; however, this effect was blocked by rimonabant, indicating the involvement of cannabinoid CB2 receptors (Matias et al., 2006).

5. Genetic Disruption. An alternative method, although not without caveats, is to make use of animals in which the PPARs are genetically disrupted. These mice have been employed on a limited number of occasions in an attempt to study the effects of cannabinoid-related molecules, although, notably, not the archetypal endocannabinoids anandamide or 2-AG, or other ligands that are known to target CB1 or CB2 receptors. Thus, antinociceptive effects of palmitoyl ethanolamide, as well as the PPARγ agonist 2-[4-[2-[[4-cyclohexylaminocarbonyl][4-cyclohexylbutyl]amino]ethyl]-phenyl]-thio]-2-methylpropanoic acid (GW7647), were lost in mice in which the ppara gene was disrupted (LoVerme et al., 2006; D’Agostino et al., 2007; Sasso et al., 2010). ppara gene disruption abrogated oleoyl ethanolamide-evoked feeding behaviors (Fu et al., 2003), oleoyl ethanolamide-mediated neuroprotection (Sun et al., 2007a), but not oleoyl ethanolamide effects on visceral pain (Suárdíaz et al., 2007) or intestinal motility (Cluny et al., 2009). Genetic disruption of PPARγ in a homozygous manner results in embryonic lethality, so heterozygous mice have been generated and studied (Kishida et al., 2001), as have mice with conditional disruption of the ppgar gene (Akiyama et al., 2002). However, the use of these mice or those in which PPARβ is genetically disrupted (Peters et al., 2000) has not been reported in investigations of endocannabinoids and their analogs.

6. Amplification of Endocannabinoid Levels and Peroxisome Proliferator-Activated Receptors. Nicotine-induced elevation of firing of ventral tegmental area neurons in anesthetized rats was inhibited by prior administration (60–120 min) of URB597, an inhibitor of the anandamide-metabolizing enzyme FAAH (Melis et al., 2008). Rimonabant failed to alter the effects of URB597, whereas 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethyllethyl)thio]-α,α-dimethyl-5-(1-methylthyl)-1H-indole-2-propanoic acid (MK886) was able to prevent the effects of URB597. The effects of URB597 were mimicked in vitro by administration of oleoyl ethanolamide, palmitoyl ethanolamide, or the PPARα agonist WY14643 in a manner sensitive to MK886 (Melis et al., 2008).
Palmitoylallylamide, described as a low-potency inhibitor of FAAH (Vandevoorde et al., 2003), evoked an inhibition of nociceptive behaviors in rat models of neuropathic pain 40 to 100 min after administration (Wallace et al., 2007). These effects were reduced after administration of rimonabant, SR144528, or MK886, dependent on the paradigm under study. In a passive avoidance paradigm, URB597 administration to rats 40 min before testing enhanced memory acquisition (Mazzola et al., 2009), whereas Δ⁹-THC administration impaired memory. The URB597 enhancement was reduced by either rimonabant or MK886. Intraplantar administration of a low, but not high, dose of URB597 reduced pain behaviors in the carrageenan model of inflammatory pain (Jhaveri et al., 2008) up to 210 min after injection. At this time, levels of anandamide and 2-AG, but not oleoyl ethanolamide or palmitoyl ethanoamidn, were elevated in URB597 and carrageenan-treated paws compared with tissue from animals treated with carrageenan alone. The antinociceptive effects of URB597 were prevented by coadministration of the antagonist but not a PPARα agonist GW9662, indicating a role for PPARα in these responses.

Blockade of endocannabinoid uptake by (5Z,8Z, 11Z,14Z)-N-(3-furanyl methyl)-5,8,11,14-eicosatetraenamide (UCM707) evoked neuroprotective effects in mouse mixed astrocytic neuronal cultures by activation of CB₁, CB₂, and PPARγ receptors (Loria et al., 2010). Application of CB₁ and CB₂ receptor antagonists, but not the PPARγ antagonist GW9662, led to an exacerbation of the excitotoxic effects of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid application. Administration of N-(4-hydroxyphenyl)-5Z,8Z, 11Z,14Z-eicosatetraenamide (AM404), a mixed inhibitor of FAAH and endocannabinoid uptake, enhanced bacterial lipopolysaccharide-evoked tumor necrosis factor-α levels in rat plasma. Antagonists of CB₁, CB₂, and TRPV1 receptors attenuated elevations of tumor necrosis factor-α levels in response to LPS and the combination of LPS and AM404, whereas PPARγ antagonism interfered only with the AM404-evoked elevation (Roche et al., 2008). Collectively, these data might be taken to indicate that PPARs are only activated significantly in vivo by endocannabinoids when endocannabinoid levels are pharmacologically amplified.

7. Regulation by Peroxisome Proliferator-Activated Receptors and Peroxisome Proliferator-Activated Receptor Ligands of the Endocannabinoid System. There is some evidence that the functioning of the endocannabinoid system can be affected by PPARs and PPAR ligands. This has come primarily from experiments with adipocytes. For example, 24 h of activation of PPARγ by ciglitazone decreased levels of 2-AG, but not anandamide, in immature, but not mature, 3T3 F442A mouse adipocytes (Matias et al., 2006). It remains to be determined whether this effect is due to a direct action on endocannabinoid synthesizing and/or metabolizing enzymes, or a consequence of cellular differentiation; interestingly, however, Pagano et al. (2007) have found that the PPARγ agonist rosiglitazone up-regulates FAAH in human adipocytes. In 3T3 L1 mouse preadipocyte cells, a related cell type, ppard gene silencing increased CB₁ receptor gene expression (Yan et al., 2007). Treatment of human adipocytes in vitro with the PPARγ agonist rosiglitazone markedly down-regulated CB₁ receptor gene expression, whereas R(+)-WIN55212 up-regulated PPARγ (Pagano et al., 2007). Treatment of human adipocytes in vitro with a different PPARγ agonist, ciglitazone, failed to alter endocannabinoids levels (Gonthier et al., 2007).

In a distinct series of investigations, a number of PPARγ agonists, including ciglitazone, pioglitazone, rosiglitazone, and troglitazone, were shown to inhibit FAAH activity in rat brain membranes, as well as in intact C6 rat glioma and RBL-2H3 rat basophilic leukemia cells (Lenman and Fowler, 2007). The low potency with which these inhibitions were induced (IC₅₀ values ~100 μM) suggests that this is an unlikely mechanism for influencing endocannabinoid levels.

8. Conclusions. Although there has yet to be a systematic investigation of the activity of all the putative endocannabinoids at all three PPAR isoforms, anandamide and 2-AG have each already been reported to activate two PPAR receptors (Table 8): PPARγ and PPARα (anandamide) and PPARγ and PPARβ/δ (2-AG). Overall, the potencies of endocannabinoids and their metabolites as PPAR agonists or antagonists are relatively low compared with their potencies as agonists of canonical cannabinoid CB₁/CB₂ receptors. This might be taken as evidence that endocannabinoids are poor candidates as PPAR ligands in vivo. However, this fails to take into account background levels of established endogenous PPAR agonists. One estimate puts intracellular levels of long-chain fatty acids at 20 μM (Forman et al., 1997), which is a level sufficient to occupy PPARs in cell-free systems. Although this background level may vary depending on the cell type and the active state of the cell, fluctuations in intracellular endocannabinoid levels may well prove sufficient to activate PPARs in vivo.

The best current evidence that endocannabinoids are endogenous agonists at PPARs in vivo derives from the use of a model of inflammatory pain. More specifically, local administration of a FAAH inhibitor has been found to induce local accumulation of both anandamide and 2-AG (but not oleoyl ethanolamide or palmitoyl ethanolamide) at a time when behavioral responses to the FAAH inhibitor could be blocked by local administration of a PPARα antagonist but not a PPARγ antagonist (Jhaveri et al., 2008).
H. Some Putative Receptors

1. Imidazoline-Like Receptors. There is evidence that at least some cannabinoid receptor agonists and antagonists can interact with a non-\(\mathrm{I}_{1}\), non-\(\mathrm{I}_{2}\) subtype of the putative imidazoline receptor that may belong to a family of G protein-coupled sphingosine-1-phosphate/LPA receptors originally known as endothelial differentiation gene receptors. These putative receptors have been reported to be activated by \(\mathrm{CP}55940\) (300 nM) and \(R^{(+)}-\mathrm{WIN}55212\) (10 and 100 \(\mu\)M) but not by anandamide (1 \(\mu\)M) and to be blocked by rimonabant (1 \(\mu\)M) and \(\mathrm{LY}320135\) (0.1 to 10 \(\mu\)M) (Molderings et al., 1999, 2002).

2. The Putative Abnormal-Cannabidiol Receptor. Since its original description as a receptor mediating the CB1/CB2-independent, endothelium-dependent vasodilator effect of anandamide and some atypical cannabinoids (Járai et al., 1999), the putative abn-CBD receptor, also called the endothelial anandamide receptor (Mukhopadhyay et al., 2002), has eluded molecular identification. The emergence of GPR55 as the first GPCR other than CB1 or CB2 receptors with high affinity for certain cannabinoid ligands has raised the question of its possible identity with the putative abn-CBD receptor.

There are a number of important parallels between the pharmacology of GPR55 and the putative abn-CBD receptor (see also section III.A.6). Thus, as summarized recently (Ross, 2009), it has been shown that in at least some GPR55 and putative abn-CBD receptor bioassays, 1) the endocannabinoid, anandamide, is active; 2) the synthetic cannabinoid receptor agonist \(R^{(+)}-\mathrm{WIN}55212\) is inactive (in all GPR55 and abn-CBD bioassays); 3) abn-CBD and the compound O-1602 (section II.C.5 and Fig. 5) (Járai et al., 1999) act as agonists, whereas their parent compound, cannabidiol, acts as an antagonist; 4) the CB2 antagonist rimonabant, but not its close structural analog AM251, can inhibit both apparent GPR55- and apparent abn-CBD receptor-mediated responses, although with lower potency than as a CB1 receptor antagonist; 5) the endogenous lipid \(\text{N-arachidonoyl serine}\) causes pertussis toxin- and \(1,3\)-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylthienyl)-2-cyclohexen-1-yl]benzene (O-1918)-sensitive, endothelium-dependent mesenteric vasodilation and thus may be an agonist of the abn-CBD-sensitive receptor (Milman et al., 2006). It has also been reported recently that nanomolar concentrations of \(\text{N-arachidonoyl serine}\) promote angiogenesis and endothelial wound healing in human dermal microvascular endothelial cells and that these effects could be partly inhibited by siRNA-mediated knockdown of GPR55 and could also be antagonized by O-1918 but not by AM251 (Zhang et al., 2010).

On the other hand, there are some key differences: 1) vasodilator effects attributed to abn-CBD receptor activation are moderately sensitive to pertussis toxin, suggestive of \(\mathrm{G}_{12}\) protein involvement, whereas GPR55 signals through \(\mathrm{G}_{12}, \mathrm{G}_{13},\) or \(\mathrm{G}_{i}\); 2) lysophosphatidyl inositol is a potent agonist of GPR55, but not of the putative abn-CBD receptor; and 3) the hypotensive/vasodilator actions of abn-CBD and its antagonism by the synthetic cannabinoid, O-1918 (Offertáler et al., 2003), persist in GPR55 knockout mice (Johns et al., 2007). However, the possibility exists that GPR55 and CB1 receptors may form heterodimers with pharmacological properties distinct from those of either one of the monomeric receptors, which may account for some or all of the above differences. Future experiments could address this question by exploring the presence of such heterodimers in various tissues under native conditions and/or by analyzing the pharmacology of cannabinoid-induced responses after the individual or joint transgenic expression of these two receptors in cells devoid of both.

Evidence has recently emerged that the putative abn-CBD receptor has features similar to those of GPR18 (McHugh et al., 2010). In BV-2 microglia and in GPR18-transfected HEK293 cells, but not in the parent HEK293 cells, abn-CBD and O-1602 potently stimulated cell migration and proliferation. Furthermore, the pertussis toxin-sensitive potent pro-migratory effect of NAGly, the putative endogenous ligand of GPR18 (section III.B.4), was inhibited by O-1918 or by the low-efficacy agonists \(\text{N-arachidonoyl serine}\) and cannabidiol. Although vascular effects were not tested in this study, it is noteworthy that in earlier experiments with human umbilical vein endothelial cells, abn-CBD-induced cell migration was found to be susceptible to inhibition by O-1918 or pertussis toxin (Mo et al., 2004). These two compounds, O-1918 and pertussis toxin, have also been reported to inhibit NAGly-induced endothelium-dependent vasorelaxation of rat mesenteric artery segments (Parmar and Ho, 2010). However, the parallel between the putative abn-CBD receptor and GPR18 is not perfect. Rimonabant, which is a low-affinity antagonist of the vascular putative abn-CBD receptor (for review, see Pertwee 2005a; Ross, 2009), had no effect on GPR18-mediated microglial migration at concentrations up to 1 \(\mu\)M (McHugh et al., 2010). Clearly, the exciting possibility that the putative abn-CBD receptor is GPR18 should be followed up.

In conclusion, there is evidence to support the contention that both GPR55 and GPR18 have at least some of the features associated with the abn-CBD-sensitive receptor. This will need to be validated by further studies.

3. A Putative Receptor for Anandamide and \(R^{(+)}-\mathrm{WIN}55212\). Investigations with C57BL/6 CB1(-/-) mice revealed that antinociception, locomotor hypoactivity, and catalepsy (immobility) responses could be elicited in these animals by anandamide but not \(\Delta^{9}\)-THC, leading Di Marzo et al. (2000) to postulate the existence of a non-CB1 receptor for this endocannabinoid agonist. Using CB1(-/-) brain membranes, they demonstrated that anandamide and \(R^{(+)}-\mathrm{WIN}55212\), but not \(\Delta^{9}\)-THC, CP55940, or HU-210, stimulated \(\mathrm{[^{35}S]}\mathrm{GTPyS}\) binding, supporting the existence of a novel non-CB1, \(\mathrm{G}_{i6}\)-coupled receptor (Di Marzo
et al., 2000; Breivogel et al., 2001). The potencies for anandamide \( \text{EC}_{50} = 3.6 \mu M \) and \( R-(+)\text{-WIN55212} \ (\text{EC}_{50} = 1.8 \mu M \) were low compared with the CB1 receptor (Breivogel and Childers, 2000), and although rimonabant antagonized both these ligands, it did so in a manner that may not have been competitive in nature because it occurred only at concentrations \( \text{IC}_{50} > 1 \mu M \) high enough to reduce basal \( [35S] \text{GTP} \gamma \text{S} \) binding (Breivogel et al., 2001). The anandamide/\( R-(+)\text{-WIN55212} \)-stimulated \( [35S] \text{GTP} \gamma \text{S} \) binding was found in brain regions that were not abundant in CB1 receptors, such as the brain stem, midbrain, and spinal cord, as well as in some areas that are well populated with the CB1 receptor, such as the cerebral cortex and hippocampus (Breivogel et al., 2001). The occurrence of non-CB1-mediated anandamide/\( R-(+)\text{-WIN55212} \)-stimulated \( [35S] \text{GTP} \gamma \text{S} \) binding was confirmed in another study carried out with C57(-/−) mouse brain membranes (Monory et al., 2002). A similar pharmacological profile is apparent in pertussis toxin-sensitive inhibition of cAMP accumulation in cultured mouse striatal astrocytes, which has been found to respond to anandamide and WIN55212, but poorly to CP55940, and to be resistant to antagonism by rimonabant (Sagan et al., 1999). In contrast to neurons, the mouse striatal astrocytes did not express immunoreactive CB1 receptors and did not exhibit \( ^{3} \text{H} \text{SR}141716 \text{A} \)-binding activity (Sagan et al., 1999).

In conclusion, the current evidence that this target, and indeed the targets described in sections III.H.1 and III.H.2, are non-CB1, non-CB2 cannabinoid receptors is based upon pharmacological profiling only, with the additional caveats that only a limited number of agents were assessed and the two identified agonists also exhibit broad CB1/CB2 pharmacological activity. Moreover, the possibility that anandamide, or anandamide metabolic products, trigger responses via other bona fide targets is an equally plausible alternative potential mechanism that remains to be investigated. A radioligand binding assay for this putative receptor based upon \( ^{3} \text{H} \text{SR}141716 \text{A} \) binding would be plagued by the abundance of brain CB1 receptors, so a selective radioligand probe would have to be developed to define the receptor binding profile. Thus, in the absence of a more comprehensive pharmacological profile and of a unique, identified protein, the naming of this pharmacological target as a definitive cannabinoid receptor cannot be justified.

4. The Putative CBsc Receptor for \( R-(+)\text{-WIN55212} \). A non-CB1, \( R-(+)\text{-WIN55212} \)-sensitive receptor has been proposed to be present in the CA1 region of the hippocampus (Hájos et al., 2001; Hájos and Freund, 2002a). This putative cannabinoid receptor has been provisionally named CBsc because of its apparent location on hippocampal Schaffer collateral/commisural axon terminals (Hoffman et al., 2005). Pharmacological evidence for the CBsc receptor is that 1 \( \mu M \) \( R-(+)\text{-WIN55212} \) reduced amplitudes of evoked excitatory postsynaptic potentials in hippocampal slice preparations from CB1(−/−) (and wild-type) CD1 mice (Hájos et al., 2001). Although this response was observed in Wistar and Sprague-Dawley rats, the response to \( R-(+)\text{-WIN55212} \) was absent in young/adult C56Bl/6 CB1(−/−) and wild-type C57BL/6 mice (Hoffman et al., 2005). It was detectable, however, in neonatal and juvenile wild-type C57BL/6 mice (Ohno-Shosaku et al., 2002). Additional supporting evidence was the failure to identify immunoreactive CB1 receptors at glutamatergic presynaptic terminals (Hájos et al., 2000). However, such immunoreactivity has since been detected using more sensitive antibodies/methods (Katona et al., 2006; Kawamura et al., 2006). In some experiments, the log concentration-response curve for \( R-(+)\text{-WIN55212} \) exhibited an apparent \( \text{EC}_{50} \) of 2 \( \mu M \) but failed to develop an asymptotic maximum even at a concentration of 30 \( \mu M \) (Hájos and Freund, 2002b; Németh et al., 2008). At such a high concentration, nonstereoselective \( R-(+)\text{-WIN55212} \) effects on N-type voltage-gated Ca\(^{2+} \) channels could be responsible for the decrement in presynaptic neurotransmission (Shen and Thayer, 1998; Németh et al., 2008). In CA1 pyramidal cells and dentate gyrus granule cells, \( R-(+)\text{-WIN55212} \) or CP55940 influenced glutamate release via a capsazepine-sensitive mechanism (Hájos and Freund, 2002b; Benninger et al., 2008). It is unlikely, however, that TRPV1 channels were responsible for this effect, because there is evidence that both capsaicin and capsazepine can reduce hippocampal glutamatergic neurotransmission in TRPV1(−/−) mice as well as in wild-type animals (Benninger et al., 2008). The putative CBsc receptor may be a TRPV1-like receptor. It is noteworthy that it is also unlikely that the proposed CBsc receptor is the same as the putative \( R-(+)\text{-WIN55212} \) receptor first identified by Breivogel et al. (2001), because evidence for the existence of this latter receptor came from experiments with C57BL/6 mouse tissue (section III.H.3).

In the absence of a more complete pharmacological characterization of the putative CBsc receptor, it remains possible that those effects on glutamate release that are induced in CB1-expressing Schaffer collaterals by cannabinoids with significant potency and that are sensitive to antagonism by either rimonabant or AM251, at least in rat and CD1 mouse tissue (Hájos and Freund, 2002b; Hoffman et al., 2005), are in fact mediated by the CB1 receptor. Moreover, those effects on glutamate release that are induced by cannabinoids with low potency, and in a nonstereoselective, and CB1 antagonist-insensitive manner, could result from perturbations of ion channel functions.

In conclusion, given the positive results obtained with \( R-(+)\text{-WIN55212} \) in CB1(−/−) CD1 mouse tissue and some negative results obtained with this cannabinoid in wild-type C57BL/6 mouse tissue, further experiments directed at establishing whether the proposed CBsc receptor truly is a novel cannabinoid receptor are clearly warranted.
IV. Phylogenetic Relationships

The sequence similarity (44% amino acid sequence identity) that the CX5 receptor (CB2) shares with the SKR6 receptor (CB1) provided crucial evidence that CX5 might be a cannabinoid receptor (Munro et al., 1993). Thus, the identification of the cannabinoid CB2 receptor heralded a new approach to the discovery of putative cannabinoid receptors: homology-based searching of gene sequence databases. Furthermore, sequencing of the human genome (Lander et al., 2001) enabled genome-wide searches for receptors structurally and/or functionally related to CB1 and CB2.

An analysis of human gene/genome sequence data carried out in 2003 revealed more than 800 genes encoding GPCRs, which were grouped on the basis of sequence relationships, into five main families named after a prototypical receptor: 1) glutamate (G), 2) rhodopsin (R), 3) adhesion (A), 4) frizzled/taste2 (F), and 5) secretin (S), with the rhodopsin family further subdivided into groups α, β, γ, and δ (Fredriksson et al., 2003b). This “GRAFS” classification system provides a useful framework both for analysis of relationships between CB1/CB2-type cannabinoid receptors and other G protein-coupled receptors and for investigation of the occurrence of putative non-CB1/CB2 G protein-coupled cannabinoid receptors in humans and other mammals.

A. CB1, CB2, and Other Rhodopsin α-Group-Type G Protein-Coupled Receptors

Cannabinoid CB1 and CB2 receptors belong to the α group of rhodopsin-type GPCRs, which is composed largely of receptors for amine-type neurotransmitters and neuromodulators (e.g., serotonin, adrenaline, dopamine) (Fredriksson et al., 2003b). Thus, CB1 and CB2 receptors are atypical of the α group in that they are activated endogenously by the lipid-type signaling molecules anandamide and 2-AG. CB1 and CB2 receptors are not, however, the only receptors in the α group that are activated by lipid ligands. The receptors in the α group that share the highest level of sequence similarity with CB1 and CB2 are a group of eight receptors that are activated by lysophospholipids. These include the sphingosine-1-phosphate (S1P) receptors (S1P1, S1P2, S1P3, S1P4, S1P5), and the LPA receptors LPA1, LPA2, and LPA3 (Chun et al., 2002). It is noteworthy that S1P exerts CB1-independent cannabinoid-like effects, including thermal antinociception, hypothermia, catalepsy, and hypolocomotion (Sim-Selley et al., 2009), whereas sphingosine and the sphingosine analog 2-amino-2-[2-[4-octylphenyl]ethyl]-1,3-propanediol (FTY720) inhibit binding of cannabinoid ligands to CB1 receptors in vitro (Paugh et al., 2006). Thus, there are some striking similarities in the pharmacological properties of the CB1 receptor and S1P receptors.

Cannabinoid CB1/CB2 receptors and the related lysophospholipid receptors belong to a distinct branch of α-type receptors (Fig. 6) that also includes receptors for melancortin peptides (MC1-MC5), adenosine receptors (A1, A2A, A2B, A3), and the orphan receptors GPR3, GPR6, and GPR12 (Elphick and Egertová, 2001; Fredriksson et al., 2003b; Elphick, 2007). Thus, on the basis of analysis of human genome sequence data, it can be speculated that, as a consequence of multiple gene duplication events, an ancestral α-type GPCR gave rise to receptors that are activated by endocannabinoids, lysophospholipids, melanocortin peptides, and adenosine. Furthermore, comparative analysis of genome sequence data reveals that adenosine receptors have a wider phylogenetic distribution than CB1/CB2-type cannabinoid receptors, lysophospholipid receptors, melanocortin receptors, and GPR3, GPR6, and GPR12 (Elphick and Egertová, 2001; Dolezelova et al., 2007). Therefore, the common ancestor of this group of GPCRs may in fact have been an adenosine receptor. Furthermore, orthologs of the CB1/CB2-type cannabinoid receptors have only been found in the phylum Chordata (vertebrates, urochordates, and cephalochordates) (Elphick, 2002, 2007; Elphick et al., 2003; Elphick and Egertová, 2005). Therefore, the duplication of a putative adenosine receptor gene that may have ultimately given rise to CB1/CB2 receptors probably occurred in a common ancestor of extant chordates.

As highlighted above, among the receptors that are closely related (on the basis of sequence similarity) to CB1 and CB2 are three receptors known as GPR3, GPR6 and GPR12 (section III.B.3). It has been reported that these “orphan” receptors are activated in vitro by the lysophospholipid S1P (Uhlenbrock et al., 2002). However, a more recent screen using the β-arrestin PathHunter assay found that these receptors were not activated by S1P, even at concentrations as high as 8 μM (Yin et al., 2009). Furthermore, GPR3, GPR6, and GPR12 are not activated by the endocannabinoids anandamide and 2-AG in this assay, suggesting that they may not be cannabinoid receptors. It is noteworthy, however, that the lysophospholipid receptor S1P1 was activated by anandamide and 2-AG, albeit only at concentrations in the micromolar range (Yin et al., 2009).

Another rhodopsin α-group-type GPCR that is of interest with respect to cannabinoid receptors is GPR119 (section III.B.6). This receptor is activated by oleoyl ethanolamide, an N-acyl ethanolamine with molecular properties similar to those of the endocannabinoid anandamide (Overton et al., 2006). There is evidence that oleoyl ethanolamide has an important physiological role as a peripherally acting agent that reduces food intake (Lo Verme et al., 2005b) and this effect of oleoyl ethanolamide may be mediated, at least in part, by GPR119 (Overton et al., 2006). Analysis of the sequence of GPR119 reveals that it shares structural similarity with adenosine receptors and amine receptors such as the 5-HT1 and 5-HT2 receptors, β- and β-adrenoceptors, and D1-type dopamine receptors. Furthermore, in a neighbor joining tree (Fig. 6) based on multiple sequence
alignment, GPR119 is positioned within the branch of rhodopsin α group-type GPCRs that include cannabinoid CB₁/CB₂ receptors, lysophospholipid receptors, melanocortin receptors, and GPR3, GPR6, GPR12, and adenosine receptors. Thus, it seems that receptors for two different N-acylethanolamines, anandamide (CB₁ and CB₂) and oleoyl ethanolamide (GPR119), originated within this branch of GPCRs. This suggests that structural features characteristic of this branch of GPCRs may, perhaps, confer on them a propensity for ligand-binding associations with the N-acylethanolamine class of signaling molecules.

B. GPR55 and Other Rhodopsin δ Group-Type G Protein-Coupled Receptors

As discussed elsewhere in this review (section III.A), the concept that GPR55 is a “cannabinoid receptor” is controversial, and GPR55 may in fact be activated physiologically by lysophosphatidyl inositol (Oka et al., 2007), which has been reported not to be a CB₁ or CB₂ receptor ligand (section II.C.5). The pharmacological properties of GPR55 will not be revisited here, but we will use this receptor as the starting point for a phylogenetic survey of “potential”
cannabinoid receptors based on sequence similarity with GPR55. First, it is important to emphasize that GPR55 does not belong to the same group of rhodopsin-type GPCRs as CB1 and CB2; GPR55 falls within the δ group, whereas CB1 and CB2 receptors are in the α group, as discussed above. Therefore, if GPR55 is activated by endocannabinoids physiologically, then it must have acquired this property independently of the CB1/CB2-type cannabinoid receptors. The δ group of rhodopsin-type GPCRs comprises a heterogeneous collection of receptors, including MAS oncogene-related receptors, glycoprotein hormone receptors, purine receptors, and ~460 odorant receptors (Fredriksson et al., 2003b).

One of the receptors that shares a high level of sequence similarity with GPR55 is GPR35. However, there is no evidence that cannabinoids or other lipid signaling molecules activate this receptor. In fact it has been found that kynurenic acid, a product of tryptophan metabolism, acts as a GPR35 agonist (Wang et al., 2006b), although the physiological relevance of this finding remains unknown. It is noteworthy that among other receptors that share high levels of sequence similarity with GPR55 are receptors that have recently been identified as lysophospholipid receptors (Fig. 7). These include GPR23 and GPR92 (sections III.B.4 and III.B.5), which are activated by LPA and are now designated LPA4 (Lee et al., 2007) and LPA5 (Lee et al., 2006), respectively, to distinguish them from the CB1/CB2-like LPA1-LPA3 receptors belonging to the α group of rhodopsin-type GPCRs. Thus, it seems that LPA receptors have evolved independently in both the α and δ branches of the rhodopsin family of GPCRs. GPR55, LPA4 (GPR23), and LPA5 (GPR92) belong to a group of closely related receptors that include P2-type purine receptors (e.g., P2Y1 and P2Y2) and a putative P2-like receptor originally designated P2Y5, which is in fact also activated by LPA and therefore has recently been designated as LPA6 (Yanagida et al., 2009). Furthermore, the P2-like receptor originally designated P2Y10 has been identified as a lysophospholipid receptor that is activated by both S1P and LPA (Murakami et al., 2008). Another receptor that is closely related to P2Y1 is GPR174 (Fig. 7), but the ligand(s) that activate this receptor are not yet known.

It is interesting that GPR55 and the lysophospholipid receptors LPA4, LPA5, and LPA6 are closely related to P2-type purine receptors because, as discussed above, CB1/CB2-type cannabinoid receptors and LPA1-3 receptors are closely related to P1-type (adenosine) purine receptors. Thus, in different branches of the rhodopsin family of GPCRs (α and δ), lipid receptors that are activated by lysophospholipids or cannabinoids may have evolved independently from receptors that are activated by purines.

Other receptors in the δ group of rhodopsin-type GPCRs that are quite closely related to GPR55 and LPA4–6 are GPR17, GPR18 (section III.B.4), and GPR34 (Fig. 7). GPR17 is a P2Y-like receptor that is activated by both uracil nucleotides (e.g., UDP-glucose) and cysteinyl-leukotrienes (Cian et al., 2006). GPR34, however, is of particular interest with respect to the endocannabinoid anandamide because it is activated by NAGly (Kohn et al., 2006), a lipoamino acid that also activates GPR92 (LPA5) (Oh et al., 2008). Furthermore, GPR34 is activated by a different lipoamino acid: lysophosphatidyl-L-serine (Sugo et al., 2006). Finally, with lipid ligands as a recurring theme, there are GPR41 and GPR43 (section III.B.1 and Fig. 7), which are activated by short-chain fatty acids. Thus, within the branch of the δ group of rhodopsin-type GPCRs that include GPR55, there are a variety of related receptors that are activated by endocannabinoid/lysophospholipid-like molecules. However, it remains to be determined whether any of these receptors have pharmacological properties of the kind that could justify their classification as a “cannabinoid receptor.”

C. Conclusions

CB1/CB2-type cannabinoid receptors are phylogenetically restricted to the chordate branch of the animal kingdom. The lysophospholipid receptors S1P1, S1P2, S1P3, S1P4, S1P5, LPA1, LPA2, and LPA3 are the GPCRs that are most closely related to CB1/CB2-type receptors. Receptors for endocannabinoid/lysophospholipid-like molecules have evolved independently in different branches of the GPCR superfamily, but CB1 and CB2 are the only bona fide “cannabinoid receptors” that have been identified thus far.

V. Cannabinoid Receptor Nomenclature: CB or Not CB? That Is the Question

The terms “cannabinoid CB1” and “cannabinoid CB2” have been used throughout this review because this is the nomenclature that is currently recommended by the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification and by its Subcommittee on Cannabinoid Receptors. It is noteworthy, however, that the adjective “cannabinoid” predates the discovery of cannabinoid receptors by many years and was originally coined to describe compounds, none of which is a structural analog of any known endocannabinoid. As a result, this term is widely used to describe not only all ligands that target CB1 or CB2 receptors but also other compounds with structures similar to the phytocannabinoid Δ⁹-THC, irrespective of whether they are or are not cannabinoid receptor agonists or antagonists. These additional cannabinoids include a number of nonpsychoactive compounds that are found in cannabis. The question arises, therefore, as to whether cannabinoid receptors should be renamed.

One possibility would be to rename these receptors after one of their endogenous agonists as is generally done for other receptors. However, selecting the most
appropriate endocannabinoid for this purpose presents a formidable challenge. Thus, it is currently unclear whether anandamide, 2-AG, or some other established endocannabinoid should be selected for this purpose. Moreover, another as-yet-undiscovered endocannabinoid may emerge in the future as the most appropriate candidate for renaming cannabinoid receptors. Hence, for the present at least, this is probably not a sensible or viable option.

Another possibility would be to rename these receptors “endocannabinoid” receptors (for example, endocannabinoid CB₁ and endocannabinoid CB₂ receptors). Such nomenclature is of course tautologous, because all receptors are expected to have endogenous ligands. Nonetheless, it would remove the current confusion created by the term “cannabinoid” and yet, by retaining the terms “CB₁” and “CB₂,” would most likely not be the cause of any significant new confusion.

These and other options will be regularly considered by the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification Subcommittee on Cannabinoid Receptors. In the meantime, it would be prudent to retain the present nomenclature for these receptors.
VI. Overall Conclusions and Future Directions

In conclusion, the endocannabinoid system seems to interact in a significant manner with several other endogenous systems. Thus, there is good evidence that CB₁ receptors form heteromers with certain other GPCRs and that this heteromerization affects the manner in which the CB₁ receptor responds to agonists (section II.D). In addition, it is generally accepted that at least some endocannabinoids, as well as Δ⁹-THC and several synthetic CB₁/CB₂ receptor agonists and antagonists, can interact with a number of established non-CB₁, non-CB₂ GPCRs, ligand-gated ion channels, ion channels, and nuclear receptors (PPARs) (section III). Of particular interest are channels or non-CB₁, non-CB₂ receptors that seem to be activated or blocked by some CB₁/CB₂ receptor ligands with potencies that differ little from those with which they target CB₁ and/or CB₂ receptors as agonists or antagonists. Examples include 1) enhancement of the activation of glycine receptors by anandamide, Δ⁹-THC, HU-210, and R(-)+WIN55212 (section III.D.3); 2) the enhancement of NMDA-induced activation of NMDA receptors by anandamide (section III.D.4); 3) the inhibition of T-type voltage-gated calcium channels by anandamide and rimonabant (section III.F.1); and 4) the inhibition of voltage-gated Kᵥ3.1 and Kᵥ4.3 potassium channels and the activation of calcium-activated potassium (BK) channels by anandamide, 2-AG, and/or R(+)-methanandamide (section III.F.2).

Some channels may be targeted by CB₁/CB₂ receptor ligands allosterically. These are 5-HT₃ and nicotinic acetylcholine receptors that can be potently activated by anandamide and certain other CB₁/CB₂ receptor ligands (sections III.D.1 and III.D.2). For some GPCRs (section III.C.3) and ligand-gated ion channels (section III.D), evidence that they can interact with CB₁/CB₂ receptor ligands has come solely from data obtained in radiolabeled ligand displacement experiments, prompting a need for further research directed at establishing whether such binding leads to receptor/channel activation or blockade. It should be noted, however, that CB₁/CB₂ receptor ligands such as anandamide, Δ⁹-THC, HU-210, 11-hydroxy-Δ⁹-THC, rimonabant, and tazarotant did not display particularly high potency in these displacement experiments.

There seems to be no correlation between the ability of compounds to activate or block CB₁ and/or CB₂ receptors and their ability to target other receptors or channels. Moreover, some receptors and channels have been found to be activated by CB₁/CB₂ receptor antagonists or antagonized or inhibited by CB₁/CB₂ receptor agonists in a CB₁/CB₂ receptor independent manner. Examples include the antagonism of GPR55 and inhibition of 5-HT₃ receptors and certain ion channels that have been observed in some experiments in response to CB₁/CB₂ receptor agonists (sections III.A.9., III.D.1, and III.F) and the activation of GPR55 and PPARγ (sections III.A.11., III.A.12 and III.G.1) that can apparently be induced by certain CB₁ receptor antagonists in some bioassay systems. It should be borne in mind, therefore, that 1) some ligands that interact similarly with CB₁ or CB₂ receptors are likely to display significantly different pharmacological profiles in both some in vitro and in vivo bioassay systems and in the clinic and 2) a cannabinoid receptor antagonist might modulate the actions of a cannabinoid receptor agonist not only directly, through competitive antagonism or by inducing an inverse agonist effect at the cannabinoid receptor (sections II.C.3 and II.C.4), but also indirectly, by producing one or more CB₁/CB₂ receptor-independent effects. Clearly, therefore, a number of CB₁/CB₂ receptor agonists and antagonists together constitute a library of compounds, each with its own distinct “pharmacological fingerprint.” It is noteworthy, too, that the terms “CB₁-selective” and “CB₂-selective” are often used to indicate that a particular ligand activates or blocks one of these two receptors more potently than the other. However, because at least some ligands that can be described in this way interact no more potently with a CB₁ or CB₂ receptor than with one or more other type of receptor or channel (section III), any use of these terms should be accompanied by an appropriate definition or caveat (section I). It is also worth noting that anandamide seems to be the first endogenous molecule to have been found capable of activating certain GPCRs, ligand-gated ion channels, ion channels, and nuclear receptors and hence members of superfamilies that display negligible structural homology.

An important question to arise from the data presented in this review is whether any known mammalian channel or non-CB₁/CB₂ receptor should be classified as a novel cannabinoid “CB₃” receptor or channel. We propose that any such receptor or channel should meet at least some of the following criteria:

1. It should be activated at its orthosteric site and with significant potency by an established CB₁/CB₂ receptor ligand.
2. It should be activated by at least one established endogenous CB₁/CB₂ receptor agonist at “physiologically relevant” concentrations.
3. If it is a GPCR, it should display significant amino acid sequence similarity with the CB₁ or the CB₂ receptor, which are members of the α group of rhodopsin-type GPCRs.
4. It should not be a “well established” non-CB₁/CB₂ receptor or channel, especially if there is already strong evidence that 1) this is activated endogenously by a non-CB₁/CB₂ receptor ligand with appropriate potency and relative intrinsic activity and 2) this is not activated endogenously by any endocannabinoid with appropriate potency and relative intrinsic activity.
5. It should be expressed by mammalian cells that are known to be exposed to concentrations of endog-
enously released endocannabinoid molecules capable of eliciting a response.

Criterion 1 is not met by any receptors or channels that seem only to be potently targeted by CB1/CB2 receptor ligands in an allosteric manner. These probably include 5-HT3 and nicotinic acetylcholine receptors (section III.D). Criteria 1 and 2 are not met by established GPCRs or deorphanized GPCRs other than GPR55, because there is, at least currently, no evidence that an endogenous or synthetic CB1/CB2 receptor agonist activates any of these with significant potency (sections III.B.7 and III.C). In addition, criterion 2 does not seem to be met by PPARs, although it should be borne in mind that intracellular levels of established endogenous PPAR agonists can be very high (section III.G.8).

Criterion 3 is not met by GPR55 but is met by GPR3, GPR6, GPR12, and other non-CB1/CB2 members of the α group of rhodopsin-type GPCRs (section IV). However, there is no pharmacological evidence that any of these non-GPR55, deorphanized receptors behaves as a cannabinoid receptor (sections III.B.3 and IV.A). Moreover, many α group rhodopsin-type GPCRs (for example, α1-3, α2-5, and β-adrenoceptors and established 5-HT, dopamine, adenosine, melanocortin, sphingosine 1-phosphate, and lysophosphatidic acid receptors) are each excluded by criterion 4 from being a novel cannabinoid receptor. The case for considering GPR55 as a non-CB1/CB2 cannabinoid receptor is further weakened 1) by the finding that it can be potently activated by an endogenous, non-CB1/CB2 receptor agonist, LPI, and 2) by the inconsistent nature of much of the pharmacological data that have been generated to-date in GPR55 experiments with CB1/CB2 receptor ligands (section III.A). Criterion 4 is also not met by calcium, potassium, or sodium channels, ligand-gated ion channels, or nuclear receptors that are targeted by CB1/CB2 receptor ligands (sections III.D., III.F., and III.G). As to criterion 5, this is not met, at least at the present time, by the putative receptors discussed in section III.H. It is also noteworthy that at least some of these putative receptors seem to be activated by endogenous or synthetic CB1 or CB2 receptor agonists with rather low potency.

It is concluded that according to the five criteria listed in this section, no channel, non-CB1/CB2 established receptor or deorphanized receptor should currently be classified or reclassified as a novel cannabinoid receptor. It is noteworthy, however, that the TRPV1 channel does seem to meet criteria 1, 4, and 5, at least in part. Thus, 1) it is activated by anandamide at the capsaicin binding site, albeit with lower potency than the CB1 receptor, and also by N-arachidonoyl dopamine; 2) it is colocalized in some neurons with CB1 receptors and hence presumably exposed to endogenously produced endocannabinoids; and 3) anandamide was the first TRPV1 endogenous agonist to be identified (section III.E.2). It is also noteworthy that there is already evidence that TRPV1 channels are activated by endogenously released anandamide, at least in the presence of a FAAH inhibitor (section III.E.2). Clearly, there is a need for further research directed at exploring the possibility that the TRPV1 channel should be regarded as being either an “ionotropic cannabinoid CB3 receptor” or a dual TRPV1/CB3 channel. Such research should also investigate the hypothesis that the extent to which endogenously released anandamide activates TRPV1 channels increases under certain pathological conditions (section III.E.2). Increased activation of this kind might mean that the TRPV1 channel would also meet criterion 2 in disease if not in health. Thus, it might well be considered acceptable for the term “physiologically relevant” in criterion 2 to encompass concentrations of an endogenously released established endocannabinoid that activate a putative cannabinoid CB3 receptor only under pathological conditions. An alternative possibility (that anandamide should be classified as a dual endocannabinoid/endovanilloid) also merits further investigation. So too does the question of whether any other non-CB1/CB2 receptor/channel that displays significant sensitivity to an endocannabinoid is ever exposed to active concentrations of this endocannabinoid when it is released endogenously in the absence or presence of drugs that inhibit its metabolism or enhance its biosynthesis. Such research should perhaps focus initially on endocannabinoid-sensitive receptors or channels that are colocalized with CB1 or CB2 receptors. It will also be important to explore both the pharmacology of GPR55 more fully and the ability of CB1/CB2 receptor ligands to target other deorphanized receptors. The search for a cannabinoid CB3 receptor should and will continue.

Acknowledgments. This work was supported in part by the Intramural Research Program of the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism (to G.K.); by the National Institutes of Health National Institute on Drug Abuse [Grants DA009789 (to R.G.P., V.D., R.A.R., R.M.), DA021696 (to K.M.), DA023204 (to M.E.A.), DA03672 (to R.G.P., R.A.R.), DA03690 (to A.C.H.), DA03934 (to R.G.P., R.A.R.), DA05274 (to M.E.A.); and by funding from the UNIK program “Food, Fitness and Pharma” (to H.S.H.).

REFERENCES

Cannabinoid Research Society, Burlington, Vermont.

Cannabinoid receptors and their ligands


CANNABINOID RECEPTORS AND THEIR LIGANDS


